Parc congress book by MCI TangenC

Hours E M C 8 1 ted from

www.PanArabRheumatology2014Dubai.com Stay Connected:

Conference Book Supported by

Congress Secretariat: MCI Middle East, Tel: +971 4 311 6300, Fax: +971 4 311 6301, Email: Parc2014@mci-group.com

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Accredi

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

President of the U.A.E

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

His Highness Sheikh Khalifa Bin Zayed Al Nahyan

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Vice President, Prime Minister and Ruler of Dubai

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

His Highness Sheikh Mohammed Bin Rashid Al Maktoum

Deputy Ruler of Dubai, Minister of Finance, UAE President of Dubai Health Authority

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om 6

His Highness Sheikh Hamdan Bin Rashid Al Maktoum

Table of Contents Welcome Message ................................................................... 11 General Information................................................................... 12 - 15 Organizing Committee .............................................................. 17 First Pan Arab Executive Committee ........................................ 17 Presidents of Rheumatology Societies in the Arab Countries ................................................................ 18 Scientific Committee ................................................................. 19 Social Committee ...................................................................... 20 Abstract Review Committee ...................................................... 20 - 21 Exhibition Floor Plan.................................................................. 23 Scientific Program ..................................................................... 25 - 28 Speaker Profiles ........................................................................ 30 - 50 Awardees ................................................................................. 52 Sponsor Profiles ....................................................................... 54 - 57

Gala Dinner ............................................................................... 63 Acknowledgement ..................................................................... 64

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Experience Dubai ...................................................................... 58 - 61

Welcome Message

Dear Friends & Colleagues, On behalf of the Scientific and Organising Committee, I would like to welcome you all to the 11th Pan Arab Rheumatology Conference – “In Support of Young Arab Rheumatologists”

The 11th PARC is a four day scientific and educational meeting designed to keep participants and delegates at the cutting edge of developments in the field of both Rheumatology and Clinical Immunology. The conference will cover multiple selected topics in paediatric and adult rheumatology as well as experimental innovative therapies presented by key opinion leaders in Rheumatology. It is a valuable opportunity to discuss issues important to clinical practice and exchange expert opinions. The conference is also offering workshops (similar to the ‘meet the Professor session’ of the ACR) to engage in scientific discussions and approaches in tackling debatable issues related to clinical practice. In keeping with the theme of the 11th PARC; we have the pleasure to provide 100 Travel Grants for Young Arab Rheumatologists, best Abstract Award, and many other awards as a humble contribution towards the support of young Arab Rheumatologists’ career. This particular conference will not only encourage the Young Arab Rheumatologists, but will also be a platform for all Rheumatologists in the region to join and share their constructive views and significant expertise. We look forward to welcoming you in Dubai.

Dr. Jamal Al Saleh Conference President President of Emirates Society of Rheumatology

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

The Pan Arab Rheumatology Conference will take place from 14th - 17th January 2014 in Dubai, United Arab Emirates. This scientific educational event is a platform to support “Young Arab Rheumatologists” and bring together many of the world’s leading Rheumatology experts in order to present and share their precious clinical knowledge, and their latest clinical research findings in various aspects related to Rheumatology.

General Information

collection and onsite registration will be operational

17.00 07.30 07.30 07.30 07.30

– – – – –

:‫مكتب الت�سجيل‬

:‫ مكاتب الت�سجيل لتوزيع ال�شارات و الت�سجيل يف املوقع متاحة يف االوقات التالية‬

19:00 – 17:00 18:00 – 07:30 18:00 – 07:30 18:00 – 07:30 14:30 – 07:30

19.00 18.00 18.00 18.00 14.30

2 014 ‫ يناير‬13 2014 ‫ يناير‬14 2014 ‫ يناير‬15 2014 ‫ يناير‬16 2014 ‫ يناير‬17

:‫ال�شارات‬

Badges:

Name badges must be visible and used at all times at the Conference Venue.

Badge Colors: Red: Speaker (all access) Black: Committees (all access) Orange: Delegate (all access except speaker preview room) Green: Exhibitor (access to exhibition only) Pink: Staff (all access) Violet: Media (all access except speaker preview room)

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Conference Bags: u Conference bags may be collected from the bag collection desk in the registration area.

CME Certification: u This scientific program is awarded 18 CME/CPD Points by Dubai Health Authority. u Certificates of Attendance for the Scientific Program will be issued online after the conference after completing an online evaluation form. Speaker Registration & Preview Room: u Speakers are requested to register at the registration desk in the Speaker Preview Room (Al Manara) NOTE: All speakers are requested to report at least 2 hours before their lecture for a final check on their presentation material in Al Manara. Conference & Workshops: u Sessions will be held in Baniyas Ballroom 1, 2 & 3, Al Remal,

Dar, Al Dana, and Al Itefaq

Al Majlis, Al Maasa, Al

.‫• يتعني �أن تكون �شارة اال�سم ظاهرة وم�ستخدمة طوال الوقت يف مكان امل�ؤمتر‬ )‫(دخول جميع الأماكن‬ )‫(دخول جميع الأماكن‬ )‫(دخول جميع الأماكن ما عدا غرفة املتحدثني‬ )‫(دخول املعر�ض فقط‬ )‫(دخول جميع الأماكن‬ )‫(دخول جميع الأماكن ما عدا غرفة املتحدثني‬

:‫�ألوان ال�شارة‬

‫ املتحدثني‬:‫الأحمر‬ ‫ جلان امل�ؤمتر‬:‫الأ�سود‬ ‫ امل�شاركون‬:‫الربتقايل‬ ‫ العار�ضون‬:‫الأخ�ضر‬ ‫ املنظمون‬:‫الزهري‬ ‫ االعالميون‬:‫البنف�سجي‬

:‫حقائب امل�ؤمتر‬

‫ • توزع احلقائب من مكتب توزيع احلقائب يف مكان الت�سجيل‬

:‫�شهادة التعليم الطبي امل�ستمر‬

‫ طبي م�ستمر‬/‫ نقطة تعلم مهني‬18 ‫ • عدد �ساعات التعليم امل�ستمر لربنامج امل�ؤمتر العلمي هي‬ .‫ معتمدة من هيئة ال�صحة بدبي‬ .‫ • ت�صدر �شهادات احل�ضور على املوقع االلكرتوين للم�ؤمتر بعد تعبئة ا�ستمارة التقييم على املوقع‬

:‫غرفة املتحدثني للت�سجيل ومراجعة املحا�ضرات‬

.)‫ • يطلب من املتحدثني الت�سجيل يف غرفة املتحدثني و املراجعة املخ�ص�صة لهم (املنارة‬ ‫ قبل �ساعتني على االقل من موعد‬,‫ على املتحدثني احل�ضور للغرفة املخ�ص�صة للمتحدثني واملراجعة‬:‫ مالحظة‬ .‫ حما�ضرتهم‬

:‫امل�ؤمتر و ور�ش العمل‬

.‫ الدانة واالتفاق‬,‫ الدار‬,‫ املا�سة‬,‫ املجل�س‬,‫ وقاعات الرمال‬1,2,3 ‫تعقد املحا�ضرات يف قاعات بني يا�س‬

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Registration Desk: Registration desks for name badge as below: 13 January, 2014 14 January, 2014 15 January, 2014 16 January, 2014 17 January, 2014

‫معلومات عامة‬

General Information Food & Beverage: u Coffee Breaks and lunch will be open to all participants. The hotel also offers a variety of all day dining restaurants to choose from. u Lunch will be held in the Garden. Exhibition: u The exhibition of the 11th Pan Arab Rheumatology Conference will be located in the Al Ameera Ballroom.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Parking: u

‫ كذلك يوجد يف الفندق جمموعة متنوعة من املطاعم املخ�ص�صة‬،‫ • ا�سرتاحة القهوة والغداء متاحة جلميع امل�شاركني‬ .‫ لتقدمي الوجبات طوال اليوم لالختيار من بينها‬ .‫ • يقدم الغداء يف حديقة الفندق‬

:‫املعر�ض‬

.‫ • املقر املحدد ملعر�ض امل�ؤمتر العربي احلادي ع�شر لأمرا�ض الروماتيزم يف قاعة الأمرية‬

:‫القواعد‬

Smoking Policy: The Grand Hyatt Dubai hotel is a non smoking venue. Participants are requested to exit the building to the designated smoking areas. Mobile Phones: All conference attendees are kindly requested to keep their mobile phones in the off mode in meeting rooms when scientific sessions are in progress.

:‫ • �سيا�سة التدخني‬ ‫ ويتعني على امل�شاركني مغادرة الفندق والتوجه �إىل الأماكن املخ�ص�صة‬،‫ ال ُي�سمح بالتدخني بفندق جراند حياة دبي‬ .‫ للتدخني‬ :‫ • الهواتف املتحركة‬ ‫ ُيطلب من جميع احل�ضور بامل�ؤمتر التكرم بغلق هواتفهم املتحركة داخل قاعات االجتماعات �أثناء انعقاد اجلل�سات‬ .‫ العلمية‬

:‫�أماكن وقوف ال�سيارات‬

.‫خدمة ركن ال�سيارات متاحة على مدار ال�ساعة يف موقع امل�ؤمتر‬

24-hour courtesy valet parking is available at the conference venue.

Prayer Room: u A shuttle bus will be available to the mosque for Friday Prayer. The bus will leave the hotel at 12:15 on Friday, 17 January, 2014 u Prayer rooms are available for ladies and gentlemen at the venue. Emergency Contact: While in Dubai during the conference, for any emergency, please contact the following people from the conference secretariat: Sharon Mascarinas Valsaraj Kottappurath +971 50 459 8033 +971 56 176 3266 Conference Secretariat:

MCI Dubai Office

P.O. Box: 124752 Dubai, United Arab Emirates Tel: +971 (4) 311 6300, Fax: +971 (4) 311 6301 Email: Parc2014@mci-group.com

:‫غرفة ال�صالة‬

‫ تغادر احلافلة الفندق يف متام‬،‫ • توجد حافلة مكوكية متوفرة لنقل امل�شاركني �إىل امل�سجد لأداء �صالة اجلمعة‬ .2014 ‫ يناير‬17 ‫ يوم اجلمعة املوافق‬12:15 ‫ ال�ساعة‬ .‫ • يوجد يف املوقع غرف لل�صالة خا�صة بال�سيدات والرجال‬

:‫جهة االت�صال يف حالة الطوارئ‬

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Rules: u u

:‫الأطعمة وامل�شروبات‬

‫ يرجى االت�صال مبكتب املنظمني على االرقام‬,‫ يف حال وجود اي حالة طارئة اثناء التواجد يف دبي حل�ضور امل�ؤمتر‬ :‫ التالية‬ ‫فال�ساراج كوتابوراث‬ ‫�شارون ما�سكارينا�س‬

+971 56 176 3266

+971 50 459 8033

:‫�سكرتارية امل�ؤمتر‬

‫جمموعة �إم �سي �آي – فرع دبي‬ 124752 :‫�ص ب‬ ‫ الإمارات العربية املتحدة‬،‫دبي‬ +97143116301 :‫ الفاك�س‬- +97143116300 :‫هاتف‬ Parc2014@mci-group.com :‫الربيد الإلكرتوين‬

RAPID DECISION.

Organizing Committee Dr. Jamal A. A. Al-Saleh Chairman United Arab Emirates Dr. Mustafa Al-Maini Co-Chairman United Arab Emirates Dr. Ali M. Al-Dhanhani General Secretary United Arab Emirates Dr. Leena Abu Shakra Member United Arab Emirates Dr. Ghita Harifi Member United Arab Emirates Dr. Manal El Sayed Member United Arab Emirates Dr. Abdulmunem Halabi Member United Arab Emirates

Rapid response and predictable outcomes with CIMZIA® 1 allow you to make an informed treatment decision at week 12.2,3,4

First Pan Arab Executive Committee

Statistically significantly greater ACR20 and ACR50 responses were achieved from week 1 and week 2, respectively, in both clinical trials compared to placebo. Responses were maintained through weeks 52 (RAPID 1) and 24 (RAPID 2)4

Dr. Samir Al-Badawi, Egypt

Cimzia® Abbreviated Product Information

Dr. Sultan Dhabera, Saudi Arabia

Name of the medicinal product: Cimzia® (Certolizumab pegol) Pharmaceutical form: Solution for injection. Each pre-filled syringe contains 200 mg certolizumab pegol in one ml. Therapeutic indications: Cimzia®, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARD) including methotrexate, has been inadequate. Cimzia® can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Posology and Method of administration: Cimzia® treatment should be initiated and supervised by a specialist physician. After proper training in injection technique, patients may self-inject with Cimzia® if considered appropriate by the physician and with medical follow up as necessary. The recommended starting dose of Cimzia® for adult patients with RA is 400 mg (as 2 injections of 200 mg each on one day) at weeks 0, 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks. MTX should be continued during treatment with Cimzia® where appropriate. The safety and efficacy of Cimzia® in children and adolescents below age 18 years have not yet been established. No data are available. No dose recommendations can be made for patients with renal and hepatic impairment as Cimzia® has not been studied in these patient populations. No dose adjustment is required in the elderly (≥ 65 years old) as population pharmacokinetic analyses showed no effect on age. Contraindications: Hypersensitivity to the active substance or any of the excipients, active tuberculosis or other severe infections such as sepsis or opportunistic infections, moderate to severe heart failure (NYHA classes III/IV). Special warnings and precautions for use: Serious infections, sepsis, tuberculosis (including miliary, disseminated and extrapulmonary disease) and opportunistic infections have been reported in patients receiving Cimzia®. Some of these events have been fatal. Patients must be monitored closely for signs and symptoms of infections inclusing tuberculosis before, during and up to 5 months after treatment with Cimzia®. Patients who develop a new infection should be monitored closely. Administration of Cimzia® should be discontinued if a patient develops a new serious infection until the infection is controlled. Physicians should exercise caution when considering the use of Cimzia® in patients with a history of recurring infection, or with underlying conditions which may predispose patients to infections including the use of concomitant immunosuppressive medications. Before initiation of therapy with Cimzia®, all patients must be evaluated for both active and inactive (latent) tuberculosis infection including a detailed medical history for patients with a personal history of tuberculosis, with possible previous exposure to others with active tuberculosis, and with previous and/or current use of immunosuppressive therapy. If latent tuberculosis is diagnosed, appropriate anti-tuberculosis therapy must be started before initiating treatment with Cimzia® and the benefit/risk balance of therapy with Cimzia® should be very carefully considered. Patients should be instructed to seek medical advice if signs/ symptoms (e.g; persistent cough, wasting /weight loss, low grade fever, listlessness) suggestive of tuberculosis occur during or after therapy with Cimzia®. TNF blockers including Cimzia® may increase the risk of reactivation of Hepatitis B Virus (HBV) in patients who are chronic carriers of the virus. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating Cimzia® therapy. Carriers of HBV who require treatment with TNF antagonists should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for up to 5 months after therapy, especially if the patient is on concomitant corticosteroid therapy. In patients who develop HBV reactivation, Cimzia® should be discontinued and effective antiviral therapy with appropriate supportive treatment should be initiated. As the potential role of TNF antagonist therapy in the development of malignancies is not known, caution should be exercised when considering TNF antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy. With the current knowledge, a possible risk for the development of lymphomas or other malignancies in patients treated with a TNF antagonist cannot be excluded.Caution should be exercised when using any TNF antagonist in chronic obstructive pulmonary disease patients, as well as in patients with increased risk for malignancy due to heavy smoking. Cases of congestive heart failure have been reported in RA patients receiving Cimzia® and it hence should be used with caution in patients with mild heart failure (NYHA class I/II). Treatment with Cimzia® must be discontinued in patients who develop new or worsening symptoms of congestive heart failure. Adverse reactions of the hematologic system, including medically significant cytopenia (e.g. leukopaenia, pancytopaenia, thrombocytopaenia) have been reported with Cimzia®. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g. persistent fever, bruising, bleeding, pallor) while on Cimzia®. Discontinuation of Cimzia® therapy should be considered in patients with confirmed significant hematological abnormalities. Use of TNF antagonists has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease, including multiple sclerosis. In patients with preexisting or recent onset of demyelinating disorders, the benefits and risks of TNF antagonist treatment should be carefully considered before initiation of Cimzia® therapy. Rare cases of neurological disorders, including seizure disorder, neuritis and peripheral neuropathy, have been reported in patients treated with Cimzia®. Severe hypersensitivity reactions have been reported rarely following Cimzia® administration in trials. If severe reactions occur, administration of Cimzia® should be discontinued immediately and appropriate therapy instituted. Since TNF mediates inflammation and modulates cellular immune responses, the possibility exists for TNF antagonists, including Cimzia®, to cause immunosuppression, affecting host defences against infections and malignancies. Treatment with Cimzia® may result in the formation of antinuclear antibodies (ANA) and, uncommonly, in the development of a lupus like syndrome. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Cimzia®, treatment must be discontinued. As no data are available, live vaccines or attenuated vaccines should not be administered concurrently with Cimzia Undesirable effects: Cimzia® was studied in 2367 patients with RA in controlled and open label trials for up to 57 months. The commonly reported adverse reactions (110%) in clinical trials with Cimzia® were viral infections (includes herpes, papillomavirus, influenza), bacterial infections (including abscess), rash, headache (including migraine), asthenia, leukopaenia (including lymphopaenia, neutropaenia), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalities, hypertension, pruritis (any sites), hepatitis (including hepatic enzyme increase), injection site reactions. Serious adverse reactions include sepsis, opportunistic infections, tuberculosis, herpes zoster, lymphoma, solid organ tumors, angioneurotic edema, cardiomyopathies (includes heart failure), ischemic coronary artery disorders, pancytopaenia, peripheral embolism and thrombosis, cerebrovascular accident, vasculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairment/nephropathy (includes nephritis). In RA controlled clinical trials, 5% of patients discontinued taking Cimzia® due to adverse events vs 2.5% for placebo. Please refer to Summary of Product Characteristics before prescribing Cimzia®. Date of Preparation: (February 2013) Date of the Approved SPC: (December 2012)

Dr. Abdullah Dhalaan, Saudi Arabia Dr. Mohammed Reslan, Bahrain Dr. Zuhair Sabbagh, Jordan Dr. Fouad Nasr, Lebanon Dr. Adnana Al-Eidan, Kuwait Dr. Adel Al-Awaidi, Kuwait Dr. Salwa Al Sheikh, Syria

References:1. Keystone EC, Curtis JR, Fleischmann RM, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011;38:990-996; doi:10.3899/jrheum.100935. 2. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226-3235. 3. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637. 4. CIMZIA [summary of product characteristics]. Bruxelles, Belgium: UCB Pharma, S.A.; 2010.

Dr. Ahmad Khalid, Egypt Dr. Ahmad Alghabari, Egypt

CIM-NBP-201-August-2013

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Dr. Humeira Badsha Member United Arab Emirates

Dr. Reda Awad, Egypt Dr. Ayman Algarf, Egypt

‫اللجنة املنظمة‬ ‫ �آل �صالح‬.‫ �أ‬.‫ جمال �أ‬/‫د‬ ‫رئي�س امل�ؤمتر‬ ‫الإمارات العربية املتحدة‬ ‫ م�صطفى املعيني‬/‫د‬ ‫رئي�س م�ساعد للم�ؤمتر‬ ‫الإمارات العربية املتحدة‬ ‫ علي م الظنحاين‬/‫د‬ ‫الأمني العام‬ ‫الإمارات العربية املتحدة‬ ‫ لينا �أبو �شقرة‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ غيتا حريفي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ منال ال�سيد‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ عبد املنعم حلبي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ حمريا باد�شا‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬

‫اللجنة التنفيذية للجمعية العربية‬ ‫لالمرا�ض الروماتزمية‬ ‫ م�صر‬,‫ �سمري البدوي‬/‫د‬ ‫ اململكة العربية ال�سعودية‬,‫ �سلطان باهربي‬/‫د‬ ‫ اململكة العربية ال�سعودية‬,‫ عبد اهلل ال�ضلعان‬/‫د‬ ‫ البحرين‬,‫ حممد ر�سالن‬/‫د‬ ‫ االردن‬,‫ زهري ال�صباغ‬/‫د‬ ‫ لبنان‬,‫ ف�ؤاد ن�صر‬/‫د‬ ‫ الكويت‬,‫ عدنان العيدان‬/‫د‬ ‫ الكويت‬,‫ عادل العو�ضي‬/‫د‬ ‫ �سوريا‬,‫ �سلوى ال�شيخ‬/‫د‬ ‫ م�صر‬,‫ احمد خالد‬/‫د‬ ‫ م�صر‬,‫ احمد الغباري‬/‫د‬ ‫ م�صر‬,‫ ر�ضا عو�ض‬/‫د‬ ‫ م�صر‬,‫ امين اجلرف‬/‫د‬

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

RAPID RESPONSE.

Prof. Hachemi Djoudi Algeria Dr. Redha Ali Bahrain Prof. Gaafer Rajab Egypt

Dr. Ala’ Al Heresh Jordan Dr. Adel Al-Awadi Kuwait

‫ عادل العو�ضي‬/‫د‬ ‫الكويت‬

Dr. Georges Merheb Lebanon Dr. Rajab Tarsin Libya Prof. Saloua Larhrissi Morocco

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

‫ ها�شمي دجودي‬/‫ د‬.‫�أ‬ ‫اجلزائر‬ ‫ ر�ضا علي‬/‫د‬ ‫البحرين‬ ‫ جعفر رجب‬/‫ د‬.‫�أ‬ ‫م�صر‬ ‫ زيد الراوي‬/‫ د‬.‫�أ‬ ‫العراق‬ ‫ عالء احلر�ش‬/‫د‬ ‫الأردن‬

Prof. Zaid Al Rawai Iraq

‫ر�ؤ�ساء اجلمعيات العربية لالمرا�ض‬ ‫الروماتيزم‬

H.E. Dr. Ahmed Al-Saidi Oman Dr. Elias Saaba Palestine Dr. Mohamad Hammoudeh Qatar Dr. Hussein Halabi Saudi Arabia

‫ جورج مرهب‬/‫د‬ ‫لبنان‬ ‫ رجب تار�سني‬/‫د‬ ‫ليبيا‬ ‫ �سلوى لرحري�سي‬/‫ د‬.‫�أ‬ ‫املغرب‬ ‫ �أحمد ال�سعيدي‬/‫�سعادة الدكتور‬ ‫عمان‬ ‫ �إليا�س �صعبا‬/‫د‬ ‫فل�سطني‬ ‫ حممد حموده‬/‫د‬ ‫قطر‬ ‫ ح�سني حلبي‬/‫د‬ ‫اململكة العربية ال�سعودية‬

Prof. Ahmed Laatar Tunisia

‫ النور العقيب‬/‫د‬ ‫ال�سودان‬ ‫ ماجدة خوري‬/‫ د‬.‫�أ‬ ‫�سوريا‬ ‫ �أحمد التار‬/‫ د‬.‫�أ‬ ‫تون�س‬

Dr. Jamal Al Saleh United Arab Emirates

‫ جمال �آل �صالح‬/‫د‬ ‫الإمارات العربية املتحدة‬

Dr. El Nour Alaagib Sudan Prof. Majda Khoury Syria

Scientific Committee Dr. Ali M. Al-Dhanhani Chairman United Arab Emirates Dr. Abdulmunem Halabi Co-Chairman United Arab Emirates Dr. Khalid Al Naqbi Member United Arab Emirates Dr. Mariam Al Shehi Member United Arab Emirates Dr. Jamal Ibrahim Member United Arab Emirates Dr. Humaid Al-Wahshi Member Oman

‫اللجنة العلمية‬ ‫ علي حممد الظنحاين‬/‫د‬ ‫رئي�س اللجنة‬ ‫الإمارات العربية املتحدة‬ ‫ عبد املنعم حلبي‬/‫د‬ ‫رئي�س م�ساعد اللجنة‬ ‫الإمارات العربية املتحدة‬ ‫ خالد النقبي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ مرمي ال�شحي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ جمال �إبراهيم‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ حميد الوح�شي‬/‫د‬ ‫ع�ضو‬ ‫عمان‬

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Presidents of Rheumatology Societies in the Arab Countries

Dr. Jamal A. A. Al-Saleh Chairman United Arab Emirates

‫ �آل �صالح‬.‫ �أ‬.‫ جمال �أ‬/‫د‬ ‫رئي�س امل�ؤمتر‬ ‫الإمارات العربية املتحدة‬

Dr. Ghita Harifi Member United Arab Emirates

‫ غيتا حريفي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬

Dr. Ahlam Mohammed Al Marzooqi Member United Arab Emirates Dr. Mohamed Hanafy Salama Member United Arab Emirates Dr. Aalaa Khalaf Abdullah Fakhroo Member United Arab Emirates Dr. Lamya Yousef Al Marzooqi Member United Arab Emirates

Abstract Review Committee

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Dr. Ali M. Al-Dhanhani Chairman United Arab Emirates

‫اللجنة االجتماعية‬

Dr. Abdulmunem Halabi Co-Chairman United Arab Emirates Dr. Manal El Sayed Member United Arab Emirates Dr. Mariam Al Shehi Member United Arab Emirates Dr. Jamal Ibrahim Member United Arab Emirates Dr. Jamal El-Tyier Member United Arab Emirates

‫ احالم حممد عبداهلل املرزقي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ حممد حنفي �سالمة‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫�آالء خلف عبد اهلل فخرو‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ملياء يو�سف املرزوقي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬

Abstract Review Committee Dr. Jihad Al Ghazali Member United Arab Emirates Dr. Humeria Badsha Member United Arab Emirates Dr. Humaid Al-Wahshi Member Oman Dr. Hanan Al Osaimi Member Kingdom of Saudi Arabia Dr. Fatima Boutaiban Member Kuwait

‫جلنة مراجعة امللخ�صات العلمية‬ ‫ جهاد الغزايل‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ حمريا باد�شا‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ حميد الوح�شي‬/‫د‬ ‫ع�ضو‬ ‫عمان‬ ‫ حنان الع�صيمي‬/‫د‬ ‫ع�ضو‬ ‫اململكة العربية ال�سعودية‬ ‫ فاطمة بوطيبان‬/‫د‬ ‫ع�ضو‬ ‫الكويت‬

‫جلنة مراجعة امللخ�صات العلمية‬ ‫ علي حممد الظنحاين‬/‫د‬ ‫رئي�س اللجنة‬ ‫الإمارات العربية املتحدة‬ ‫ عبد املنعم حلبي‬/‫د‬ ‫رئي�س م�ساعد اللجنة‬ ‫الإمارات العربية املتحدة‬ ‫ منال ال�سيد‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ مرمي ال�شحي‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ جمال �إبراهيم‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬ ‫ جمال الطري‬/‫د‬ ‫ع�ضو‬ ‫الإمارات العربية املتحدة‬

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Social Committee

22 ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

ARLAR

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Exhibition Layout

ACTEMRA® Active ingredient: Tocilizumab. Mechanism of action: Actemra is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) IgG1 subclass. Indications: Treatment of moderate to severe active rheumatoid arthritis in adult patients who have either responded inadequately to, or who were intolerant to treatment with disease-modifying antirheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. Actemra may be used alone or in combination with methotrexate (MTX) and/or other standard DMARDs. Actemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. Dosage and administration: The recommended dose of Actemra is 8 mg/kg body weight administered once every 4 weeks by intravenous infusion over 1 hour. Actemra should

clude the possibility of hepatitis reactivation in patients on Actemra therapy. Preventive vaccinations: Neither live nor attenuated vaccines should be coadministered with Actemra as no clinical data are available on the safety of such combinations. Influence on serological diagnosis of infections: A potential impact of Actemra therapy on the serological diagnosis of specific infections cannot be excluded as no studies have been undertaken on this question. Effects on full blood count: Cases of decreased neutrophil and platelet counts have been observed on treatment with Actemra 8 mg/kg combined

16:45 - 17:45

caution is essential when administering Actemra to patients with active hepatic disease or hepatic impairment. Reactivation of hepatitis B: Rare cases of hepatitis B reactivation have been observed with the use of immunosuppressants in rheumatoid arthritis. Currently available data do not definitely ex-

16:30 - 16:45

It must be ensured that standard treatment for anaphylactic shock is available and at hand before administering Actemra. Active hepatic disease and hepatic impairment: An increase in transaminases may occur during Actemra therapy, in particular during coadministration with MTX. For this reason,

15:00 - 16:30

infection. Patients with latent tuberculosis should receive standard antimycobacterial therapy before being started on Actemra. Hypersensitivity reactions: Anaphylactic reactions or other severe hypersensitivity reactions have been observed in 0.3% of patients. They were observed after 2–5 infusions.

11:00 - 11:15

Lipid parameters: Elevations in lipid parameters including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides were observed in patients treated with Actemra. Tuberculosis: Before initiating Actemra therapy a work-up should be undertaken for latent tubercular

07:30 - 8:00

caution. Diverticulitis: Events of diverticular perforation as complications of diverticulitis have been reported, patients presenting with symptoms potentially indicative of complicated diverticulitis, such as abdominal pain, should be evaluated promptly for early identification of gastrointestinal perforation.

Time

active severe infections. Warnings and precautions: Infections: Actemra should not be administered to patients with active infection. In patients with recurrent infections or in those with disease predisposing to infection (for example, diverticulitis or diabetes), treatment should be administered with

14:15 - 15:00

be administered under strict aseptic conditions by qualified healthcare professionals after being diluted in a sterile and pyrogen-free solution of 0.9% sodium chloride to a total volume of 100 ml. Contraindications: Hypersensitivity to the active substance or to any of the constituent excipients and

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

BSR Workshop: Statistics for Rheumatologists Marwan Bukhari

Bristol-Myers Squibb Satellite Symposium: Confirming the Path to Optimize Patient Benefits Marco Matucci

Pan Arab Rheumatology Administrative Meeting

Osteoarthritis and Osteoporosis Research Interest Group

Coffee Breaks

Dermatological Signs of Connective Tissues Diseases Anwar Al Hammadi

Lunch & Prayer

New Bridge Satellite Symposium: Rapid Response: A Predictable Future Edward Keystone, Peter Nash 13:15 - 14:15

10:00 - 11:00

12:15 - 13:15

SLE in the ERA of biologics, or are we there yet? Ahmed Al Shaikh

09:00 - 10:00

Communicating Risk and Benefit Abstract Session: Rheumatoid Engaging Patients Arthritis Peter Nash

Treat to Target in RA & SpA Maxime Dougados

08:00 - 09:00

11:15 - 12:15

Abbvie Satellite Symposium: Management Updates in Spondyloarthritis and Rheumatoid Arthritis Maxime Dougados

Early SpA: Referral and Management Jurgen Braun

Update on Juvenile Scleroderma Sulaiman Al-Mayouf

Lupus Nephritis Ahmed Al Shaikh

Coffee Breaks

Registration and signing for the workshops

Al Remal Baniyas 2 & 3 Baniyas 1

Abbreviated Prescribing Information

UAE-ACT05-07/13

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Al Maasa

January 14th, 2014

Al Majlis

WHEN COMBINATION IS NOT AN OPTION

ONE BIOLOGIC MONOTHERAPY STANDS OUT

How to Read MSK X-Ray: Upper Physical Examination Skills: Limb Upper Limb Arthur Bookman Hani Almoallim / Nahid Janoudi

Poster Viewing: Rheumatoid Arthritis

Allied Health II What is the Role of Rheumatology Nurse and How it Improves Patient’s Outcome Francesca Leone Trainees Session: How to Approach Patient with Polyarthritis Ala’ Al Heresh

Al Dar

Al Dana

Allied Health I What is the Role of Rheumatology Nurse and How it Improves Patient’s Outcome Francesca Leone

Al Itefaq

Myth Busters - Controversies in For GP: Approach to Patients the Management of with Inflammatory Arthritis Osteoporosis Ala’ Al Heresh Peter Nash

Scientific Program - Day 1, 14 January, 2014

with standard DMARDs. Interactions: The cytokines that stimulate chronic inflammation inhibit synthesis of the CYP450 enzyme. For this reason any potent antiinflammatory such as Actemra can be expected to normalise production of the CYP450 enzyme. This effect is clinically relevant for CYP450 substrates with a low therapeutic index that are given at individually tailored dosages. When initiating Actemra therapy, it is important to take this effect into account in patients treated with such drugs (for example, warfarin) or to monitor their concentrations (ciclosporin), and adjust the individual dose of the drug as needed. Pregnancy: There are insufficient data on the use of Actemra in pregnant women. Actemra must not be used in pregnancy, except if considered absolutely essential by the attending physician. Lactation: It is not known whether Actemra is excreted in human milk. Undesirable effects: Upper airways infections, nasopharyngitis headache, dizziness, hypertension,increase in transaminases, neutropenia, hypercholesterolemia, stomatitis, gastritis, cellulitis, rash, pruritus. Available forms: Solution for dilution for infusion, available in 80 mg (4ml), 200 mg (10 ml) and 400 mg (20 ml) vials, each containing 20 mg/ml. Special storage instructions: Store at 2–8°C (in the refrigerator), do not freeze; store the vial in its original pack, protected from light.

Full prescribing information is available upon request. In case of any adverse event occurring with ACTEMRA, please forward details to e-mail: dubai.drug_safety@roche.com Hoffmann-La Roche Ltd. (Dubai Branch) P.O.Box 27309, Dubai, U.A.E. Phone: +971 4 8164800, Fax: +971 4 8800212 www.roche.com

26 Pregnancy & Rheumatic Diseases Munther Khamashta

Use of DMARDS and Biologics in Pregnancy Monika Ostensen

09:00 - 10:00

10:00 - 11:00

January 15th, 2014 Al Majlis

Roche Satellite Symposium: A Focus on Tailored Therapy in Arthritis Haider Al Attia, Cem Gabay, Khaled Al Saeid Lunch & Prayer

12:15 - 13:15

13:15 - 14:15 14:15 - 15:00

Pan Arab Rheumatology Administrative Meeting

Pulmonary Hypertension in Rheumatic Diseases Bashar Kahaleh

Classification criteria for the Cryoglobulinemic Vasculitis – validation study Gaafar Ragab

Macrophage Activation Syndrome in Children with Systemic Juvenile Rheumatoid Arthritis Adel Wahadneh & Update on Auto inflammatory Syndromes Basil Fathallah

Abstract Session: Osteoarthritis and Osteoporosis

Al Remal

Pan Arab Rheumatology Administrative Meeting

Management of Antiphospholipid Syndrome Munther Khamashta

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

16:45 - 17:45

16:30 - 16:45 BSR Workshop: Practical Guide: New Bridge Workshop: Biologic Conducting Research in your Treatment for JIA what do we know Clinical Practice Timothy Beukelman, Ronald Laxer Christopher Deighton

What can we learn from local Arab Vitamin D, Health and MSK Effect: registries: the experience of Evaluation and Guidelines Kuwait Registry for Rheumatic Ghada El-Hajj Fuleihan Diseases Adeeba Al-Herz

15:00 - 16:30

The Value of Testing for HLA-B27 for the Diagnosis of SpA in the Arab World Mohammed Hammoudeh

An Integrated View on the Management of Fibromyalgia Jose Antonio Da Silva

An Update: Sjogren Syndrome Arthur Bookman

11:15 - 12:15

11:00 - 11:15

10:00 - 11:00

Updates on Orphan Diseases Ali Jawad

09:00 - 10:00

Baniyas 2 & 3

Amgen Satellite Symposium: The Role of RANK-RANKL Pathway in the Treatment of PMO Samir Elbadawy

Difficult Cases in Pediatric Rheumatology Basil Fathalla Amr Daia Mohammed E. Abu-Shukair Ashwaq AlE’ed

08:00 - 09:00

Outcome Measures in Rheumatology Yasser El Miedany

Baniyas 1

BSR Workshop: Conducting a Systematic Literature Review Munther Khamashta

Basics in Ultrasound Examination with a Hands on Session (beginners) Rachid Bahiri

Lunch & Prayer

AstraZeneca Satellite Symposium: The Emerging Role of the Fixed Dose Combination “Vimovo” in Managing Arthritis Pain Jamal Al Saleh, Mustafa Al Maini

07:30 - 8:00

Time

16:45 - 17:45

16:30 - 16:45

15:00 - 16:30

14:15 - 15:00

Pfizer Satellite Symposium: Treating RA today - Facing the Challenges Alejandro Balsa, Hendrik Schulze-Koops

January 16th, 2014 Al Majlis

New Bridge workshop: Barriers to Treat to Target: Related to Patient Derived Outcomes Edward Keystone

MSK X-Ray of the Spine Arthur Bookman

Coffee Breaks

Approach to the Vasculitis and Vasculitis Mimics Raashid Luqmani

Joint Injection Session Jamal Teir & Gamal Ibrahim

Al Dar

Paediatric Interest Research Group

Physical Examination Skills: Lower Limb Hanan Al-Osaimi

RA Interest Research Group

Physical Examination Skills: The Back Hanan Al-Osaimi

Poster Viewing: Osteoarthritis and Osteoporosis

Clinical Cases in Musculoskeletal Ultrasound (intermediate) Rachid Bahiri

Coffee Breaks

Registration and signing for the workshops

Al Maasa

Pfizer Workshop

Coffee Breaks

Evidence Based Management of How to Read MSK X-Ray Lower Ankylosing Spondylitis Limb Khalid Alnaqbi Arthur Bookman

Monitoring Pregnancy in Patients with Rheumatic Diseases Munther Khamashta

Al Dana

SPA Interest Research Group

Interpreting Dexa Scan and the New Fracture Risk Assessment Algorithm Samir Elbadawy

Poster Viewing: Connective Tissue Diseases & Vasculitis & Pediatric Rheumatology & Spondyloarthropathies, Fibromyalgia and Back Pain

12:15 - 13:15

13:15 - 14:15

Patient Education: Fundamentals of Therapeutic Education in Lupus Patients and Steps to Build a Successful Therapeutic Education Program Ahlem Chaib

Trainees Session: How to HCV Infection & Approach Patient with Musculoskeletal Manifestations Monoarthritis Hassan Bassiouni Hani Almoallim/Nahid Janoudi

Periodic Fever: Update on Classification and Management Ali Jawad

Al Dana

11:15 - 12:15

Al Dar

Patient Education: Fundamentals of Therapeutic Education in Lupus Patients and Steps to Build a Successful Therapeutic Education Program Ahlem Chaib

Coffee Breaks

Registration and signing for the workshops

Al Maasa

Abstract Session: Spondyloarthropathies, Fibromyalgia and Back Pain

Abstract Session: Connective Tissue Diseases & Vasculitis & Pediatric Rheumatology

Al Remal

ANCA Associated Vasculitis: An Update on Management Raashid Luqmani

11:00 - 11:15

Janssen Satellite Symposium: Golimumab, What is on it for my Patients Juan J Gómez-Reino

Baniyas 2 & 3

08:00 - 09:00

Baniyas 1

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om 07:30 - 8:00

Time

Developing a Questionnaire: A How to Workshop Yasser El Miedany

Al Itefaq

Approach to Inflammatory Myopathies Hussein Halabi

Al Itefaq

Scientific Program - Day 2, 15 January, 2014 Scientific Program - Day 3, 16 January, 2014

28 ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Scientific Program - Day 4, 17 January, 2014

CMY

Speaker Profile

Speaker Profile • Had The American board in Internal Medicine in 1998, The Canadian board in Internal Medicine in 1999 and The Canadian Board in Rheumatology in 2000 • Fellow of The American College of Physicians • Fellow of The Royal College of Physicians and Surgeons of Canada • Contributed in many local and international conferences and has many publications in her fields

Assoc. Prof. Anwar Al Hammadi Consultant and Head of Dermatology at DHA Rashid Hospital United Arab Emirates

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Consultant and Head of Dermatology at Dubai Health Authority and MediClinic City Hospital Clinical Associate Professor of Dermatology at Dubai Medical College American Board Certified Dermatologist Fellow of Royal College of Physicians in Canada Dr. Al Hammadi finished his residency training from McGill University in Canada, followed by Fellowship in Dermatologic surgery from Mount Sinai School of Medicine in New York. He has more than 30 publications in scientific journals and book chapters. He frequently gives lectures on medical dermatology nationally and internationally.

Dr. Ala’ Al-Heresh President of Jordan Rheumatism Society Head of Rheumatology Unit King Hussein Medical Center Royal Medical Services Jordan

Dr. Adeeba Abdulla Al-Herz Consultant Rheumatologist Kuwait • • • • •

Consultant Rheumatologist in Al-Amiri Hospital, Kuwait Graduated from The Faculty of Medicine, Kuwait University in 1993 Completed her post-graduate training in Internal Medicine at McGill University, Montreal in 1998 Completed her post-graduate training in Rheumatology at The University of British Columbia, Vancouver in 2000 Completed her specialized training in Systemic Lupus Erythematosus (SLE) and Vasculitis at The University of Toronto, Canada in 2001

Assoc. Prof. Sulaiman M. Al-Mayouf Consultant, Head of Pediatric Rheumatology King Faisal Specialist Hospital & Research Center Saudi Arabia Consultant and Head of Pediatric Rheumatology at King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh and Associate Professor at Medical College, Alfaisal University. Dr. Al-Mayouf finished his residency training from KFSHRC, followed by Fellowship in Pediatric Rheumatology from Hospital for Sick Children in Toronto.He is a board member for the Saudi Rheumatology Society and national coordinator for the Pediatric Rheumatology International Organization (PRINTO).Dr. Al-Mayouf has more than 60 publications in scientific journals as well as many abstracts. Frequent lecturing nationally and internationally in Pediatric Rheumatology

Assoc. Prof. Hani Almoallim Associate Professor Medical College, Umm Alqura University Saudi Arabia Associate Professor, Department of Medicine, Medical College, Umm Alqura University, Makkah, Saudi Arabia. Vice Dean, Medical College, Umm Alqura University (UQU), Makkah, Saudi Arabia, May 2012 – present time. Trained in University of British Columbia, Vancouver, Canada from 1998 to 2004. Has got the Canadian and the American board in internal medicine and rheumatology. Medical Education Diploma, University of Dundee in 2005. Consultant Rheumatologist, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. Supervisor, Alzaidi Chair of Research in Rheumatic Diseases, UQU, Oct 2010 – present time. Head of curriculum committee, Medical College, UQU and leading a major change in curriculum development in the college. Has established a standard training program teaching approach to early arthritis with hands-on training on musculoskeletal examination. This was published in MedEdPORTAL (www.mededportal. org/publication/9398). The program was conducted in several cities in Saudi Arabia. A workshop was presented in 12th European Congress of Internal Medicine, Prague, Oct 4/2013. Over 40 publications in peer reviewed journals in internal medicine, rheumatology and medical education. Editor of a book on systemic lupus erythematosus, ISBN 978-953-51-0266-3. Publisher: InTech, March, 2012.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Dr. Reem Abdwani Oman

Speaker Profile

Sample of publications: Almoallim H, et al, Sensitivity of standardised musculoskeletal examination of the hand and wrist joints in detecting arthritis in comparison to ultrasound findings in patients attending rheumatology clinics. Clin Rheumatol. 2012 Sep;31(9):1309-17. PMID: 22673791 Almoallim H, et al, Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: Three case studies from Saudi Arabia. Joint Bone Spine. 2013 Feb 28. PMID: 23453475

Dr. Khalid Alnaqbi Consultant Rheumatologist Head of Rheumatology Department Medical Institute, Al Ain Hospital United Arab Emirates

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Present Positions Supervisor Faculty for the Family Medicine Residency, Al Ain Hospital. December 2013 - Present Core Faculty (Rheumatology and Research rotations) for the Internal Medicine Residency, Al Ain Hospital. September 2013 – Present Director of Early Arthritis Clinic – August 2013 – Present Head of Rheumatology Department, Medical Institute, Al Ain Hospital, UAE, July 2013 – Present Consultant Rheumatologist, Medical Institute, Al Ain Hospital, UAE, September 2011 – Present

Degrees Master of Medical Sciences (MSc), Institute of Medical Science, University of Toronto, November 2012, Bachelor of Medicine, Bachelor of Surgery (MBBS), United Arab Emirates (UAE) University, College of Medicine and Health Sciences (CMHS), Al-Ain, UAE, July 2002 Education & Training University of Toronto, Toronto, Canada Spondyloarthritis Fellowship Program, July 2010 – December 2012 Adult Rheumatology Fellowship, July 2008 – June 2010 General Medicine Residency Program, January 2004 – June 2008 Pre-entry assessment period, November 2003 – January 2004 UAE University Teaching Hospitals, Al-Ain, UAE Rotating internship, September 2002 – August, 2003

Dr. Hanan Al-Osaimi Head of Rheumatology Section King Fahed Armed Forces Hospital, Jeddah Saudi Arabia Past: Rheumatology Fellow, University of Toronto, Canada 2006/2007. Chairperson of education committee, medical department. Director of Saudi board residency training program, medical department, KFAFH. Member of Saudi board residency training program interview committee (Saudi council) Member of Training & Recognition committee (Saudi council) Member of mortality and morbidity, KFAFH Deputy director of medical department Present: • Head of Rheumatology section. King Fahed Armed Forces Hospital, Jeddah • Consultant internist & Rheumatology • Member of Osteoporosis committee, K.F.A.F.H • Member of Saudi Rheumatology Society • Member of Saudi advisory group (Task force ) of Saudi association for pulmonary hyperten sion, SAPH • Emirate society of Rheumatology (ESR) chapter lead from Saudi Arabia at GCC • Member of the organizing committee of Abu Dhabi advanced rheumatology review course 2012, also for 2013 • Member of bed utilizatlization in KFAFH

Dr. Ahmad AlShaikh Saudi Arabia

Prof. Rachid Bahiri Morocco - Professor of Rheumatology since January 2005 - Rheumatology department, El Ayachi Hospital, CHU Rabat Salé, Morocco - Head of the El Ayachi Hospital, Center of musculoskeletal diseases, CHU Rabat Salé, Morocco - General Secretary of the Moroccan Society for Rheumatology since 2008 - Coordinator of RHUMECHO, Academic certificate of Ultrasound in Rheumatology at the Faculty of Medicine in Rabat. - National coordinator of the Ankylosing spondylitis Moroccan guidelines 2010 - Member of the French Society for Rheumatology

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Speaker Profile Prof. Hassan Bassiouni Professor of Rheumatology President of The Updated Rheumatology Foundation Al-Azhar University Egypt

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Born in 1955, Prof Hassan Mohamed Bassiouni graduated from Ain-shams University in Dec 1978. He received his training as a registrar in the Dept of Rheumatology and Rehabilitation till the acquisition of the Master degree in Oct 1982. Moving to Al-Azhar Univ he worked as a assistant lecturer until he got his Doctorate in 1985. Having received training in Bath, England under the supervision of Prof Allan St J Dixon, in 1981-82 to finish his thesis on septic arthritis, he went to Belgium in 1986 to work on osteoporosis with the eminent Prof Dequeker and made an important publication on the morphometry of vertebral bodies in osteoporosis. Becoming a full professor of rheumatology in 1995, he conducted a lot of research on a diversity of rheumatic diseases but the current interest is Osteoarthritis particularly that of the knees. In 2009 he announced the “Updated rheumatology foundation” the first society to award annually a prize for the best published article in rheumatology. The prize is in the name of Prof Mohamed Bassiouni. At the moment he is conducting research in the field of Clinical trials, Phonoarthrography, vitamin D and arthritis.

Dr. Arthur Bookman Program Director, Division of Rheumatology Associate Professor of Medicine University of Toronto Canada Arthur A.M. Bookman MD FRCPC. Dr. Bookman is the Program Director for the Division of Rheumatology, University of Toronto. He is the Coordinator for the Multidisciplinary Sjogren’s Clinic at the University Health Network. Dr. Bookman sits as the Board Chair of the Journal of Rheumatology and the Chair of the Medical Advisory Board of the Sjogren’s Society of Canada. He holds the award as Distinguished Rheumatologist of the Canadian Rheumatology Association, and the Dafna Gladman Award for sustained contribution to the Division of Rheumatology at the University of Toronto. He is a past President of the Canadian Rheumatology Association. Dr. Bookman holds several awards for excellence in teaching, and has been teaching MSK radiology to residents in weekly sessions since 2002. He has published over 40 peer review articles as well as many abstracts and book chapters. He sits on advisory boards for the CRA, the Arthritis Society of Canada (past Chair), as well as several pharmaceutical boards.

Dr. Jürgen Braun Medical Director Rheumazentrum Ruhrgebiet, Herne Ruhr Universität Bochum Germany University in Berlin, Germany. Prof.Braun is certified as a specialist in rheumatology, internal medicine, laboratory medicine, physical therapy and sports medicine. Currently he is head of the ‘Rheumazentrum Ruhrgebiet’ in Herne, one of the major hospitals in Germany that are specialised in the management of patients with rheu¬matic diseases. Prof.Braun gives educational lectures at the Ruhr University in Bochum. Furthermore he holds a guest professorship in rheumatology at the Charité in Berlin. Some years ago he was appointed as a full professor by the University of Regensburg. Prof.Braun is a fellow of the Royal College of Physicians in Edinburgh (FRCPE). In 2011 and 2012 he was the President of the German Society of Rheumatology DGRh, and he still is its Vice-president. Prof.Braun is currently the scientific lead of the German Academy for Rheumatologic Education RhAk. A recipient of several awards, including the EULAR price in 2003, and the Carol Nachman Research Award in 2000, the AS Patients Association (DVMB) Award in 1996, and the Tosse-Research Award in Pediatric Rheumatology in 1998, Prof.Braun was appointed inaugural R.Inman lecturer at the University of Toronto. In 2008 he was President of the International Congress of Spondylo-arthritis in Gent, Belgium. Prof. Braun has been invited to speak about his research at the National Institutes of Health, the ACR, EULAR and APLAR Congresses, and several other international venues including the national meetings of the British, the Scottish, the Irish, the Indian, the Scandinavian, the Danish, the Dutch, the Belgian, the French, the Italian, the Spanish, the Portugese, the Greek, the Turkish, the Maroccan, the Emiraty, the Russian, the Chinese and the German Society of Rheumatology. As one the leading specialist in the field of the spondyloarthritides, Prof. Braun has published almost 500 papers on different aspects of this subject. Prof. Braun is a member of the Steering Committee of the Assessments in Ankylosing Spondylitis (ASAS) Working group and he is a member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Dr. Marwan Bukhari Consultant Rheumatologist Clinical Lead for Rheumatology University Hospital of Morecambe Bay NHS Foundation Trust United Kingdom

Dr Marwan Bukhari is a consultant rheumatologist and clinical lead for rheumatology at the University Hospital of Morecambe Bay NHS Foundation Trust, and holds honorary contracts with Lancaster, Liverpool and Manchester Universities. Clinical interests include early inflammatory arthritis and epidemiology. Dr Bukhari is head of the informatics group for the British Society for Rheumatology, associate editor of the Journal Rheumatology and undergraduate lead for years two and four for medicine at Lancaster University. He has been involved in several national BSR/BHPR clinical guidelines.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Speaker Profile Dr. Ahlem Chaib Consultant Physician Internal Medicine Specialist Internal Medicine II, Autoimmune Diseases, Lupus and Aniphospholipid Syndrome French National Reference Center, Pitie Salpetriere Hospital France

Since 2009, she has been working in the Autoimmune, Lupus and Antiphospholipid National Reference Center. She achieved her MD degree from Algiers University, and completed her internal medicine residency at Pierre & Marie Curie University. She had been a clinical fellow at the internal medicine unit of both, Pitié-Salpètrière and Cochin Hospital - her experience revealed a particular interest in Lupus, antiphospholipid syndrome and autoimmune diseases. In 2005, she was awarded a research grant, upon which, she joined the Lupus Unit at St Thomas’s Hospital in London as a research and clinical fellow, attending patients with lupus and autoimmune diseases. Simultaneously, was a research post-graduate student at King’s College London with a special interest in cardiovascular risk in Lupus.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Currently she holds a consultant position and runs the internal medicine day case unit. She is also investigator and actively involved in many International clinical trials. After completion of a patient education training program, she has been actively involved in the development of the national program of therapeutic lupus patient’s education within the Lupus and Antiphospholipid syndrome National Reference Center. Dr Chaib is a member of national lupus expert committee. She has markedly contributed in the design of the Lupus guide for diagnostic and therapeutic National protocol.

Prof. Jose Antonio Pereira Da Silva Head, Rheumatology Department Faculty of Medicine University of Coimbra Portugal Prof. Pereira da Silva received his medical degree. from the Faculty of Medicine at the University of Coimbra in 1982 and his Ph.D. in Medicine/Rheumatology from the University of London in 1993, with a thesis dedicated to the study of sex hormone influence upon inflammation-induced cartilage degradation. He is currently Full Professor of Medicine and Rheumatology at the University of Coimbra, and Head of the Rheumatology Department at the University Hospital of Coimbra. He has a long standing dedication to Medical Education, consolidated in his activities as Chairman of EULAR Standing Committee for Education and Training (from 2001 to 2005) and President of the European Board of Rheumatology from 2006 to 2010. He has published over 150 papers in National and International peer-reviewed journals and currently serves in the Editorial Board of several scientific journals in the area of Rheumatology. His current research interests are especially focused in Osteoporosis, Fibromyalgia and the psychological domains of rheumatic diseases. He especially prides himself on being an educator and a practicing clinician dedicated to translating research into the best possible practice to the benefit of patients.

Prof. Fereydoun Davatchi Professor of Medicine, Head Division of Rheumatology Honorary Head, Rheumatology Research Center Tehran University of Medical Sciences Iran

University Education: MD, Faculté de Médecine, Paris, 1957-1965. Diplôme d`Etat de Rhumatologie (Board Certificate of Rhumatologies), Paris, 1965-1968 Major Professional Services: • Professor of Medicine, Head Division of Rheumatology, Tehran University of Medical Sciences Since 1969, Professor Emeritus (2010) • Chairman, APLAR Special Interest Group (SIG) for Behcet`s Disease, from 1992 • APLAR COPCORD Coordinator, 2010 • Associate Editor (2004), Senior Editor (2010), International Journal of Rheumatic Diseases • Associate Editor of BMC Musculoskeletal Disorders from 2010 • Member of International Advisory Board of the journal “Lupus” from 2005 • Editorial Board Member of Clinical Rheumatology from 2010

Dr. Chris Deighton President, British Society for Rheumatology Consultant Rheumatologist, Royal Derby Hospital United Kingdom

Dr. Chris Deighton is the President of the British Society for Rheumatology and a Consultant Rheumatologist at Royal Derby Hospital. He is also an Honorary Associate Professor at the School of Medical & Surgical Sciences in Nottingham University. He graduated in 1984 from Newcastle Medical School, and undertook his rheumatology training in the North-East. His MD thesis was on the genetic epidemiology of rheumatoid arthritis. In 1993, he was awarded a MRC Travelling Fellowship to Berkeley University to extend his expertise in genetic analysis. In 1993, he also started his first Consultant job in Nottingham, and was Clinical Director in Rheumatology for 5 years. Dr. Chris was attracted to a new consultant job in Derby following the opening of the Graduate Entry Medical School in 2003. His NHS post has protected time for research and delivering and developing undergraduate teaching. Beside the presidency of the BSR, he is currently a Clinical Advisor to the NICE Rheumatoid Arthritis Management Guidelines a lead on the British Society for Rheumatology Biologics Guidelines and a Lead for the Musculoskeletal Specialist Interest Group, Trent Clinical Research Network

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Speaker Profile Prof. Samir ElBadawy Prof of Rheumatology Cairo University Egypt

Scientific Societies Member of the the Societé Française de Rhumatologie American College of Rheumatology Executive Board Member of Osteoarthritis Research Society Morocco Society of Rheumatology (Honor Member)

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

• • • • •

Chairman of the EULAR Standing Committee for Clinical Studies including Therapeutic Trials (ESCISIT) EULAR-ACR Officer liaison Vice-President of ASAS (ASsessment of Ankylosing Spondylitis) EULAR President Centre of Excellence in Rheumatology attributed by EULAR

since 1983 since 1989 since 1993 since 2003 2003-2007 2007-2009 since 2003 2009- 2011 since 2005

Scientific Journals Advisory editor (past or present) • Acta Reumatologica Portuguesa • Arthritis and Rheumatism • British Journal of Rheumatology (Rheumatology) • Clinical Experimental Rheumatology • EULAR Journal (Annals of Rheumatic Diseases) • Journal of Rheumatology • Osteoarthritis and Cartilage • Revue du Rhumatisme • Scandinavian Journal of Rheumatology • International Journal of Advances in Rheumatology Key Point of Clinical Activities and Research * Chief of the Department of Rheumatology, Cochin Hospital * Fields of research: - Outcome measures in rheumatic diseases (osteoarthritis, bone diseases, inflammatory rheumatic disease)

Scientific Degrees - M.B.B.Ch Cairo University, June 1965 - Diploma of General Medicine, Cairo University, June, 1968 - Diploma of Rheumatology & Rehabilitation, Cairo university, June, 1969 - M.D. Rheumatology, Cairo University, June, 1974 Employment - President of October 6th University, Sep. 1996 - Dec. 1999 - Dean of Beni-Sweif Faculty of Medicine, Cairo University, June 1994 - Sep. 1996 - Dean of Student Affairs & Education, Faculty of Medicine, Cairo University, Sep. 1990 - April 1994 Scientific Activities in Medical Journals - Editorial Board of Clinical Rheumatology Journal - Editorial Board of the Egyptian Rheumatology Journal - Secretary General of ILAR (International League for Associations of Rheumatology) for four years from 2004 to 2008 - President of the Egyptian Osteoporosis Prevention Society - Ex. President of the Pan-Arab Osteoporosis Society - Ex. President of the Egyptian Society For Joint Diseases & Arthritis

Dr. Yasser El Miedany Consultant Rheumatologist (UK) Lead Clinician Metabolic Bone Disease Musculoskeletal US trainer Darent Valley Hospital United Kingdom After receiving his medical degree from Ain Shams University, Cairo, Egypt in 1984, Dr. El Miedany completed an internship and residency at the University Hospitals. He furthered his training in rheumatology at the Centre for Rheumatic Diseases, Royal Infirmary, Glasgow University (UK); where he carried out his MD thesis about pulmonary affection in patients with rheumatoid arthritis and whether it is genetically related. Dr. El Miedany got Diploma in internal medicine, Master’s degree and MD in Rheumatology as well as FRCP (UK). Dr. El Miedany is Clinical Professor of Rheumatology and Rehabilitation at Ain Shams University, Egypt since 2005 and currently he is consultant rheumatologist, Darent Valley Hospital, England. Prof. El Miedany is a fellow of the Royal College of Physicians (FRCP, London), American College of Rheumatology, British Society for Rheumatology and is a regional coordinator for the Paediatric Rheumatology International Organization (PRINTO). Prof. El Miedany has authored over 100 manu-

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Prof. Maxime Dougados Professor of Rheumatology AP-HP COCHIN Hospital France

Speaker Profile

scripts, focusing on the management of rheumatoid arthritis, spondyloarthritis and osteoporosis which have been published in peer-reviewed journals, and has authored over 200 abstracts, which have been presented at rheumatology conferences world-wide. He has been an invited speaker at many international rheumatology meetings and symposia worldwide in which he has discussed the diagnosis and management of rheumatoid arthritis as well as spondyloarthritis. Dr. El Miedany has special interest in Musculoskeletal Ultrasonography, a growing speciality in the rheumatology field. He has published several manuscripts studying this tool of assessment. Dr. El Miedany was an early proponent of the aggressive treatment of rheumatoid arthritis and the importance of measuring disease activity / patient reported outcome measures in order to help guide treatment decisions. Recently he has been involved in implementing Treat to Target approach for inflammatory musculoskeletal conditions in standard clinical practice. Dr. El Miedany is a reviewer for many peer-reviewed journals including Arthritis & Rheumatism, the Annals of Rheumatic Disease and the Journal of Rheumatology. He is an Associate Editor for BMC musculoskeletal.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Prof. Ghada El-Hajj Fuleihan Professor of Medicine, Director Calcium Metabolism & Osteoporosis Program WHO Collaborating Center for Metabolic Bone Disorders Division of Endocrinology, Department of Internal Medicine American University of Beirut-Medical Center, Lebanon

Dr El-Hajj Fuleihan is Professor of Medicine, founding Director of the Calcium Metabolism and Osteoporosis Program, and of the WHO Collaborating Center for Metabolic Bone Disorders, at the American University of Beirut, Beirut, Lebanon. Dr El-Hajj Fuleihan obtained her MD degree from the American University of Beirut and completed her residency and fellowship at the New England Deaconess and Brigham and Women’s Hospitals, Harvard Medical School, Boston. She received a master in Public Health from the Harvard School of Public Health and directed the Calcium Metabolism Research Unit at the Brigham and Women’s Hospital, Harvard Medical School for several years prior to moving back to her Alma Mater. Dr. El-Hajj Fuleihan’s major research interests revolve around, osteoporosis, hypovitaminosis D, metabolic bone disorders, calcium-sensing, and women’s helath issues. Her vitamin D program spans epidemiology to cohort as well as randomized controlled trials across the lifespan. She has published on her topics of interest in over 120 publications, including peer-reviewed first tier original investigations, several invited Editorials and commentaries in the New England of Medicine and Journal of Clinical Endocrinology and Metabolism, Nature Reviews Endocrinology, and has written several reviews and chapters in major reference textbooks and in the CD Rom UpTodate, http://taff.aub.edu.lb/~webcmop/publications.html. Dr El-Hajj Fuleihan is founding President of Lebanese Society for Osteoporosis and Metabolic Bone Disorders OSTEOS, serves on the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF), the Board of Directors of the International Bone and Mineral Society (IBMS), and is a member of the Research Ethics Committee of the WHO Eastern Mediterranean Office, and of the Nutrition Committee, WHO Geneva. She serves on the Annual Meetings Steering Committees of the IBMS, the Endocrine Society, and is a full faculty member for of the Internation-

al Society of Clinical Densitometry (ISCD) certification courses. She serves on the editorial boards of the Journal of Bone and Mineral Research, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Densitometry, and Metabolism Clinical and Experimental. She co-chaired the Task Force for the 2010 IOF-ISCD FRAX International Initiative; and led the 2011 IOF Middle East-Africa Osteoporosis Audit.

Dr. Basil Fathalla Senior Consultant, Pediatric Rheumatology Hamad General Hospital Qatar Basil Fathalla, MD, ABP, ABP-Rhu, FAAP, FACR is a senior consultant and head of section of pediatric rheumatology at Hamad General Hospital since 2011. Dr. Fathalla completed his medical school at the School of Medicine – Damascus University, Syria during the period 1989 – 1996 with Excellent grade and completed Pediatric Residency training at Henry Ford Hospital in Detroit, USA during the period 1997 – 1999 and was selected as a chief resident for the year 1999 – 2000. Dr. Fathalla then pursued subspecialty pediatric rheumatology training at the Floating Hospital for Children / The New England Medical Center / Tufts University in Boston USA during 2000 - 2003. Dr. Fathalla is American Board Certified in Pediatrics and Pediatric Rheumatology and is fulfilling requirements for maintenance of certification. During the period from 2003 – 2011 Dr. Fathalla gained his experience in the field of pediatric rheumatology through academic positions in various tertiary care hospitals including St. Christopher’s Hospital for Children in Philadelphia and Children’s Hospital of Michigan in Detroit with academic positions as assistant professor of pediatrics at Drexel University and Wayne State University respectively. In addition, Dr. Fathalla held the position of head of section of pediatric rheumatology at Hamad General Hospital intermittently with academic position as assistant professor of pediatrics at Weill Corneal Medical School – Qatar Branch. Dr. Fathalla has several publications and active research projects in different aspects of pediatric rheumatology and has been a guest speaker in international conferences and grand rounds in the USA and Middle East.

Dr. Hussein Halabi President of Saudi Society of Rheumatology Consultant Rheumatologist Director of Academic and Training Affairs KFSH&RC Saudi Arabia • • • • • • • •

Graduated from King Abdulaziz University, KSA in 1996 Internal medicine residency at University of Western Ontario, Canada 1998-2001 Rheumatology fellowship at University of British Columbia, Canada 2001-2003 Double board certified, (American and Canadian board in internal medicine and rheumatology) Former President of Pan Arab Association for Rheumatic Diseases 2010-2012 Current President of Saudi Society for Rheumatology Consultant rheumatologist, Director of academic and training affairs, King Faisal Specialist Hospital and Research Center - Jeddah Several publications, national and international speaker

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Speaker Profile Dr. Mohammed Hammoudeh

The American Board Of Internal Medicine The American Board Of Internal Medicine, Rheumatology Health Care Quality Certification Board

Sept. 1980 Nov. 1982 Nov. 1999

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

June 1982 till present: Consultant, Internal Medicine and Rheumatology 1998-till Present: Editor In Chief: Qatar Medical Journal 2006-till present: Member of the editorial Board of Egyptian Rheumatology Journal 2010 till present: Member of the editorial Board of World Journal of Rheumatology

Positions Held: Jan 2006 - Jan. 2008 President, Pan Arab Rheumatology Society May 1998 - Jan 2000 Director, Quality Management July 1995 - Mar 1997 Medical Director June 1987 - May 1990 Medical Director Oct 1986 - June 1987 Chairman Of Medicine Oct 1983 - Sept 1986 Acting Chairman Of Medicine Oct 1982 - Sept 1983 Assistant Chairman, Dept Of Medicine. June 1982 - Dec 2012 Chief Of Rheumatology Research Interest : SpA, Vitamin D and Clinical trials in RA and SpA Publications : 77

Dr. Kimme Hyrich Reader, Rheumatic Disease Epidemiology, University of Manchester Honorary Rheumatology Consultant, Manchester Royal Infirmary United Kingdom Dr Hyrich completed her Bachelors of Science and her medical degree at the University of Manitoba in Canada. She did her training in internal medicine in Winnipeg, Canada and a fellowship in rheumatology at the University of Toronto. She subsequently worked as an Arthritis Society of Canada Research Fellow at the Arthritis Research UK Epidemiology Unit in Manchester. She is currently a Reader in Rheumatic Disease Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary, Manchester, UK. Dr Hyrichâ&#x20AC;&#x2122;s main research interests centre on outcomes in inflammatory arthritis in both adults and children, with a particular focus on pharmacoepidemiology. She is a principal investigator for a number of studies including the British Society for Rheumatology Biologics Register, the Biologics for Children with Rheumatic Diseases Cohort Study, the Rheumatoid Arthritis Medication Study and the Childhood Arthritis Prospective Study. She has published extensively on the short and long-term effectiveness and safety of biologics in a number of rheumatic diseases including JIA, as well as on determinants of treatment response.

Qualifications M.B. Ch.B Garyounis University Benghazi-Libya January 1987 ABMS Arab Board Medical Specialisation In General Medicine The Arab League Council Of Arab Health Ministers April 1993 MRCP (UK) Membership Of The Royal College Of Physicians, United Kingdom July 1998 M.MedSci (Rheumatology) Master Of Medical Science In Rheumatology University Of Birmingham (UK) October 1999 FRCP (London). RCP number: 55070 Fellowship Of The Royal College Of Physicians, London May 2009 FRCP (Ireland) Fellowship Of The Royal Of Physicians, Ireland June 2011 Current Post: Full Time Consultant Rheumatologist 15th Nov 2010 till now Dr Sulaiman Al Habib Medical Centre Dubai Health Care City, Dubai, UAE

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Dr. Gamal Ibrahim Consultant Rheumatologist Dr Sulaiman Al Habib Medical Centre United Arab Emirates

Consultant Internal Medicine and Rheumatology Qatar

Speaker Profile

Dr. Nahid Janoudi Consultant-Internist- Rheumatologist DSFH (Dr Sulaiman Fakeeh Hospital Saudi Arabia Dr Nahid Janoudi is currently working as Consultant Internist Rheumatologist at DSFH, Jeddah since 2011. She is an Internal Medicine Residency Program Director for Saudi Board post graduate program in DSFH, Jeddah. Certificates - Arab Board Internal Medicine 2000 - Rheumatology Fellow in KFSH & RC Jeddah Experience - I worked in KFSH&RC Jeddah from 2002-2011 as an Assistant Consultant Rheumatologist - I was the Co-chairperson of Organizing Committee in PARC 2012 in Jeddah Research - I had 4 papers were published from 2011-2013 - Chapter of Heamatological Menifistation in SLE

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speakers In many conferences. In Saudi Arabia, Prague and I am looking forward for PARC 2014

Prof. Bashar Kahaleh Professor and Chief Division of Rheumatology and Immunology University of Toledo Medical Center United States of America

Education and Training BCP Biology, Chemistry and Physics-Damascus University, 1966 Damascus, Syria M. D., Medicine Damascus Medical School, 1972 Damascus, Syria Post Graduate Medical Education, Fellowships 1972-1973 Intern in Medicine, Huron Road Hospital,Cleveland, Ohio 1973-1975 Resident in Medicine, Medical College of Ohio at Toledo,Toledo, Ohio 1975-1976 Chief Resident in Medicine and Instructor, Medical College of Ohio at Toledo, Toledo, Ohio 1976-1978 Fellow (Rheumatology and Immunology), Medical University of South Carolina, Department of Medicine,Charleston, South Carolina Employment/Previous Appointments 1978-6/30/82 Assistant Professor of Medicine, Medical University of South Carolina, Department of Medicine, Division of Rheumatology and Immunology, Charleston, South Carolina 7/15/82-7/15/83 Acting Director, Medical University of South Carolina,Department of Medicine, Division of Rheumatology and Immunology, Charleston, South Carolina 6/30/82-4/1/91 Associate Professor of Medicine, Medical University of South Carolina, Department of Medicine, Division of Rheumatology and Immunology,Charleston, South Carolina

Prof. Ali S M Jawad Clinical Professor of Rheumatology Barts and the London SMD, Queen Mary, University of London United Kingdom Professor Ali S M Jawad, MSc (Medical Immunology), FRCP (Lon), FRCP (Edin), DCH, DMedRehab, is a Consultant Rheumatologist at Barts Health NHS Trust and Clinical Professor of Rheumatology at the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London. He was Director of Medical & Dental Education and Foundation Training Programme Director at Bartâ&#x20AC;&#x2122;s and the London NHS Trust. He is host and International Clinical Examiner for the RCP. Since 2008, he has been Associate International Director (Middle East and North Africa) at RCP, International Development Lead at Barts Health and International Co-Chair at The British Society for Rheumatology. He has published widely: 3 books, chapters in several books and more than 120 articles in learned journals. He has won several grants (ÂŁ400K), runs a metabolic bone service and is currently researching the role of RANK ligand in patients with RA and osteoporosis.

4/1/91-present Professor of Medicine, Chief Division of Rheumatology and Immunology, University of Toledo Medical Center, Department of Medicine, Toledo, Ohio Research interests are focused on the pathogenesis of the vascular disease in scleroderma. More recently the focus shifted towered understanding the role of epigenetics regulation of gene expression in scleroderma pathogenesis.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Speaker Profile Prof. Munther Khamashta Professor/Consultant Physician Director of The Graham Hughes Lupus Research Laboratory St Thomas’ Hospital, London United Kingdom

Munther Khamashta is Professor/Consultant Physician and Director of The Graham Hughes Lupus Research Laboratory at St Thomas’ Hospital, London, and runs a large lupus pregnancy clinic. He studied medicine in Barcelona and internal medicine in Madrid, Spain, where he developed an interest in connective tissue diseases and received his PhD. He was awarded the MRCP in 1999 and FRCP in 2002. He joined the Lupus Unit in London 25 years ago and has been instrumental in developing it into an internationally recognised tertiary centre receiving referrals from all over the UK.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Professor Khamashta has served on the Editorial Boards of many journals, including Clinical & Experimental Rheumatology, Lupus, and Current Rheumatology Reviews. He is a member of several professional societies, including the International Society of Internal Medicine, the American College of Rheumatology, and the Spanish Society of Rheumatology. He is a member of the Steering Committee of the International Board on the Study of Antiphospholipid Antibodies and of the Steering Committee of the International Advisory Board for Systemic Lupus Erythmatosus. He has received several international awards for his work in lupus, including The European League Against Rheumatism (EU LAR) and International League Against Rheumatism (ILAR) prizes.

Professor Khamashta has a strong research interest in lupus and connective tissue diseases, with a special interest in pregnancy and antiphospholipid syndrome. He has published extensively in lupus, Hughes’ syndrome, and related areas, with more than 600 original papers.

Mrs. Francesca Leone Rheumatology Clinical Nurse Specialist St George’s Hospital, London United Kingdom Francesca Leone attended University College Hospital, London and qualified as a liscenced registered nurse in 1985. She worked as a senior nurse in a surgical and medical ward in University College Hospital in London . In 1990 she started working in a private hospital, the Churchill Clinic in London with Professor Graham Hughes and it is here where she developed an interest in autoimmune diseases such as Lupus and rheumatoid arthritis. In 2003 she was given the opportunity to join a large rheumatology department based in St George’s Hospital, a large teaching hospital in London. She continues to work for this department as a Clinical Nurse Specialist ( CNS) focusing mainly on patients with rheumatoid arthritis . She also participates in the research activities and clinical trials being carried out in the department.She runs 2 nurse-led clinics,one annual review clinic and Biologic therapy clinic on a weekly basis.

Prof. Raashid Luqmani Rheumatology/Consultant Rheumatologist Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford United Kingdom Professor of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford. I trained in Nottingham as an undergraduate. After junior posts in Birmingham and Nottingham, I completed general medicine training in Stoke on Trent before going to Southampton as a rheumatology research fellow, then to Birmingham to complete my senior registrar training in rheumatology. My first consultant/senior lecturer post in rheumatology was in Edinburgh from 1994 to 2005, after which I moved to Oxford and received a personal chair in rheumatology in 2011. My research and clinical interest is in systemic vasculitis.I manage a specialist vasculitis service as well as being responsible for supporting the general rheumatology service. I have published a number of papers in vasculitis and have research grants to develop better diagnostic strategies in vasculitis, to develop patient reported outcome measures and to assess long term prognosis in vasculitis. My current projects focus on diagnosis and classification of vasculitis, the role of ultrasound as a diagnostic tool in suspected giant cell arteritis; the risk of aortic aneurysm development in giant cell arteritis; long term damage in small vessel vasculitis. I have published a textbook of rheumatology and orthopaedics, a pocket book on rheumatoid arthritis and coordinated national and international guidelines on various aspects of rheumatic diseases.

Assoc. Prof. Peter Nash University of Queensland Australia Peter Nash is Associate Professor at the Department of Medicine, University of Queensland, Australia, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia. He is a Chairman of the Professional Affairs Committee and member of the Scientific Advisory Board, of the Australian Rheumatology Association and member of the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. He also serves as a member of the International Steering Committees for EPOSS , GRAPPA and T2T initiative. Professor Nash and his group at the Rheumatology Research Unit have been involved with the pivotal registration clinical trials for all modern targeted biological therapies. He has 100 publications, 4 book chapters, and acts as reviewer for a number of rheumatology journals. His special interests include metabolic bone disease, novel therapeutics and Caravaggio.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Speaker Profile Prof. Monika Østensen Professor, Department of Rheumatology National Center of Pregnancy and Rheumatic Disease University Hospital of Trondheim Norway

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Monika Østensen, MD, PhD, is a consultant for the Center for Pregnancy and Rheumatic Diseases at the University Hospital of Trondheim, Norway, as well as a consultant for the High Risk Pregnancy Unit, Department of Rheumatology at the Sörlandet Hospital in Kristiansand, Norway. Dr. Østensen completed her medical degree at the School of Medicine at the University of Freiburg in Germany and received her board certification in Rheumatology in Tromsö, Norway. Subsequently, Dr. Østensen was a research fellow at the University of Texas Health Science Center, where she studied the modulation of natural killer cell function. Through the years, her main focus of research has been the interaction of pregnancy and rheumatic disease, the use of immunosuppressive drugs during pregnancy and lactation and issues of reproduction in rheumatic disease. From 1991 to 1999, Dr. Østensen served as Professor and Head of the Department of Rheumatology at the University Hospital of Trondheim, where she founded the Center for Mothers with Rheumatic Diseases. From 1999 until 2009, she was Head of the Center for Preconceptional Counselling and Pregnancy in Patients with Rheumatic Diseases at the University Hospital of Bern, Switzerland. At present she is the convenor of a EULAR task force working with antirheumatic drugs during pregnancy and lactation. Dr. Østensen has published book chapters, articles in international medical journals, and patient materials on pregnancy issues. Monika Østensen is a honorary member of the Norwegian Association of Rheumatologists and of the Swiss Association of Rheumatologists.

Prof. Gaafar Ragab Professor Cairo University Egypt Dr. Gaafar Ragab graduated from the Faculty of Medicine, Cairo University 1976 where he got his degrees in Internal Medicine: MSc 1980 and PhD 1985. He served his faculty as a Resident, Assistant Lecturer 1980, Lecturer 1985, Assistant Professor 1990, and Professor 1995 till now. He spent a sabbatical year 1989 at the UAB, USA in the department of Clinical Immunology and Rheumatology. He headed the Clinical Immunology & Rheumatology Unit affiliated to the Internal Medicine Department 1995-2013. He is Chief of the Internal Medicine Department’s Research Committee since 2010. He is Fellow of the American College of Rheumatology (ACR) since 1989. He is a Co-founder of the Egyptian Society of Immunology and Rheumatology (EGYSIR) which he headed as its President 2010-2013. He was chosen as President of the Egyptian League Against Rheumatism (ELAR) annual meeting in Alexandria 2013. He is member of the Advisory Board of the Egyptian Society of Internal Medicine (ESIM) and its Journal and will serve this year as President of ESIM annual meeting Cairo 2014. He is the associate editor of the Journal of Advanced Research (JARE), the interdisciplinary publication of Cairo University, in charge of its medical branch. He won the prize of honour, Cairo University, for the great efforts in international publications, for the Year 2008.

Dr. Elsadeg Sharif Consultant Pediatric Rheumatologist Child Health Institute Al Ain Hospital United Arab Emirates I graduated from the medical school at the university of Tripoli in January 1992 and obtained the MBBCh. I finished my internship in 1993 and joined the pediatric department at Al Jala children hospital in Tripoli as a pediatric trainee, during that time I obtained the Diploma in child health in April 1995. I moved to the UK in 1997 to complete my training in pediatrics. I was awarded the MRCPCH in October 1998. I did a master degree (MSc) in pediatric rheumatology at the University of Birmingham in the year 2000. During my master course I was a clinical fellow at the pediatric rheumatology department at Birmingham children hospital. I had the opportunity to work with one of the leaders in pediatric rheumatology professor T Southwood. My dissertation was about PCR testing of Synovial fluid in children with JIA. I did further training in general pediatrics and pediatric rheumatology.I was appointed as consultant at Hull Royal Infirmary, UK in June 2006. One of my challenges was to established pediatric rheumatology service working closely with my adult rheumatology colleagues. I was appointed as head of the pediatric department in 2007 and then as clinical director of the children services in 2010.I moved to the UAE in March 2013 and joined the staff at Al Ain hospital as a consultant pediatrician with special interest in pediatric rheumatology. Since I moved to AAH I have been working very hard to start the pediatric rheumatology service for the local community.

Prof. Sami Salman Professor in Rheumatology Internal Medicine in College of Medicine University of Baghdad Iraq Professor in Rheumatology and Internal Medicine in College of Medicine, University of Baghdad. In 1973, he got his MB, ChB from Baghdad Medical College, went to France in 1979 where he got the Degree of CES in Sports Medicine, Then went to England and worked as Registrar in Rheumatology, Royal Bath hospital, Harrogate, N.Yorks,UK and St. James’ hospital, Leeds, UK from 1981-1985 when he got the MRCP in 1984 and the Diploma of Rheumatology and Rehabilitation in 1985. After returning to Iraq and working in the University of Baghdad, became Professor in 2000 and got his FRCP (Glasgow) in 2005. Elected Chairman of Education Committee of APLAR 20102012, Associate Editor of the International Journal of Rheumatic Diseases from 2012 to-date. Prof. Salman has more than thirty articles published in local and international journals and received frequent invitations to speak in national and international rheumatology events.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Speaker Profile

Dr. Jamal Teir Consultant Rheumatologist Al Ain Hospital United Arab Emirates

Dr. Jamal Teir gained his medical university qualification, then furthered his education by completing a post-graduate higher medical qualification in the United Kingdom. He has trained in well-known hospitals, including university hospitals whilst in the UK. He has gained membership of Royal College of Physicians in the UK (MRCP), and gained a certificate of training in Rheumatology (CCST) and gained a fellowship of Royal College of physician (FRCP). Since 1st November 2006, he worked as a Consultant Rheumatologist in United Kingdom until he moved to Al Ain Hospital towards the end of 2010.

CMY

Dr. Adel Al-Wahadneh

Chief of Pediatric Immunology & Allergy & Rheumatology Section Chief of Bone Marrow Transplantation for Primary Immunodeficiency Group Queen Rania Children Hospital, King Hussein Medical Center Royal Medical Services Founder of the Pediatric Immunology, Allergy and Rheumatology Service since 1998 Founder of primary immunodeficiency hematopoietic stem cell transplantation program since 2003 NCC Director-Pediatric Rheumatology Trials organization-Jordan Reprehensive, International consortium Primary Immunodeficiency 33 published clinical trials in pediatric immunology and rheumatology 30 abstracts in local, national and international conferences 63 stem cell transplantation in primary immunodeficiency

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Senior Consultant Pediatric Immunologist & Rheumatologist Pediatric Immunology, Allergy & Rheumatology Unit Queen Rania Children Hospital/King Hussein Medical Center Jordan

‫‪Awardees‬‬ ‫‪Pan Arab Masters of Rheumatology Awardees‬‬ ‫‪Prof. Mohammed Hassan Bassiouni Egypt‬‬ ‫‪Prof. Zaid Al Rawi Iraq‬‬ ‫‪Dr. Badie Al-Saleh Jordan‬‬ ‫‪Prof. Najia Hajjaj-Hassouni Morocco‬‬ ‫‪Prof. M’hamed Hamza Tunisia‬‬ ‫‪Dr. Majda I. Khoury Syria‬‬

‫احلا�صلون على درجة املاج�ستريالعربي يف امرا�ض الروماتيزم‬ ‫ ‬ ‫الربوفي�سور حممد ح�سن ب�سيوين‬ ‫ ‬ ‫الربوفي�سور زيد الراوي‬ ‫ ‬ ‫الدكتور بديع ال�صالح‬ ‫ ‬ ‫الربوفي�سورة جنية حجاج ح�سوين‬ ‫الربوفي�سور حممد حمزة ‬ ‫الدكتورة ماجدة �إ‪ .‬خوري ‬

‫م�صر‬ ‫العراق‬ ‫الأردن‬ ‫املغرب‬ ‫تون�س‬ ‫�سوريا‬

‫& ‪Best Abstract Award‬‬ ‫‪Young Arab Rheumatologist Abstract Awardees‬‬ ‫‪Best Abstract Award‬‬ ‫‪ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om‬‬

‫‪Young Rheumatologist Best Abstract Award‬‬ ‫‪Morocco‬‬

‫ ‪Dr. Bendriss Nora‬‬

‫ ‪First Place:‬‬

‫‪Iraq‬‬

‫ ‪Dr. Aws Khalaf‬‬

‫ ‪Second Place:‬‬

‫‪Tunisia‬‬

‫ ‪Dr. Olfa Saidane‬‬

‫ ‪Third Place:‬‬

‫جائزة اف�ضل ملخ�ص علمي و جوائز اف�ضل امللخ�صات العلمية لل�شباب‬ ‫العربي املخت�ص بامرا�ض الروماتيزم‬ ‫جائزة �أف�ضل ملخ�ص علمي‬ ‫كو�سوفو‬ ‫ ‬ ‫الدكتور زانا ابراهيمي‬ ‫ ‬ ‫جائزة �أف�ضل ملخ�ص علمي لل�شباب العرب املتخ�ص�صني يف علم الأمرا�ض الروماتيزمية ‬ ‫املغرب‬ ‫املرتبة الأوىل‪ :‬الدكتورة نورا بندري�س ‬ ‫العراق‬ ‫املرتبة الثانية‪ :‬الدكتور �أو�س خلف ‬ ‫تون�س‬ ‫ ‬ ‫املرتبة الثالثة‪ :‬الدكتورة الفة �سعيدان‬

‫‪ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om‬‬

‫‪53‬‬

‫‪Dr. Zana Ibraimi Kosovo‬‬

‫‪52‬‬

Sponsor’s Profiles

Platinum Sponsor

Main Sponsor

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

company focused on pharmaceuticals, biologics, and diagnostics. NBP specializes in in-

licensing, acquiring, registering and commercializing FDA and EMA approved therapeutics

Platinum Sponsor

to address the unmet medical needs of diseases with high regional prevalence and bridge access gap to bring innovation to the Middle East, Africa and Turkey (AfMET) markets. Our focus is on products for oncology care, metabolic disorders and gastro intestinal conditions, immunology and central nervous systems diseases. Our integrated and unique strategy of regional expertise and strong international network makes NBP the partner-of-choice, offering a one-stop-innovative model for pharmaceutical, biotechnology and other healthcare companies seeking to access the rapidly expanding markets of the AfMET.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, ophthalmology, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

NewBridge Pharmaceuticals, (NBP) is a first-in class ventures-backed specialty therapeutics

Sponsor’s Profiles

Gold Sponsor AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. www.abbvie.com

Silver Sponsor Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders. www.bms.com

Silver Sponsor

In health care, there’s no time to waste. There are diseases to be treated, medicines to be developed, and lives to be enhanced and transformed. At the Janssen Pharmaceutical Companies of Johnson & Johnson, we focus on some of the most devastating diseases and the most complex medical challenges of our time, across the following five therapeutic areas: • Cardiovascular and Metabolism • Immunology • Infectious Diseases and Vaccines • Neuroscience • Oncology Janssen comprises companies with nearly 40,000 employees in more than 150 countries around the world. We work within and beyond our communities, globally, to bring innovative treatments for serious unmet medical needs. We make extraordinary efforts to help people enjoy ordinary moments. Today’s medical challenges are far more complex than ever before. That’s why we never limit the search for new medicines to our own four walls. We look at the world as our lab, seeking innovative ideas wherever they occur. We believe in connecting our own expertise and capabilities with those of others, seeking the most creative minds in every field. Together, we can solve problems and find transformational solutions. At Janssen, we collaborate with the world for the health of everyone in it.Yet it’s not just about finding new treatments. We look at these medical challenges in a broader context. We go beyond the medicine – ensuring people have the information, education and support to access the treatments they need and use them correctly for the best possible results. Helping people live full and happy lives inspires us. And promising new science and technology spur us on.

Bronze Sponsor

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Gold Sponsor

‫اخــتبـروا دبي‬

‫‪Experience Dubai‬‬

‫‪About Dubai‬‬

‫نبذة عن دبي‬ ‫دبي – جوهرة الإمارات العربية املتحدة املكنونة‪ .‬ونظ ًرا لل�صحاري وال�شواطئ‬ ‫التي حتدها من كل جانب‪ ،‬ف�إن دبي ت�ستعر�ض اختالف وا�ضح يف االجواء‪ ،‬بد ًءا‬ ‫من الثقافة الإ�سالمية ال�ساحرة وو�صولاً �إىل كونها كربى العوا�صم الع�صرية‬ ‫العالية التقنية يف القرن احلادي والع�شرين‪ .‬وت�أتي املدينة تعب ًريا رائ ًعا عن ر�ؤية‬ ‫عظيمة وجت�سيدً ا لكل معاين النجاح والفر�ص احلقيقية‪.‬‬ ‫و�سيجد اجلميع غايته يف مدينة دبي‪ ،‬بد ًءا من ع�شاق العطالت الباحثني عن‬ ‫اال�ستجمام واال�سرتخاء بعيدً ا عن �ضغوط العمل‪ ،‬وو�صولاً �إىل امل�سافرين يف‬ ‫رحالت العمل بح ًثا عن جتربة جديدة مليئة بالإثارة‪ .‬ح ًقا ُتعد هذه الإمارة وجهة‬ ‫عاملية النعقاد امل�ؤمترات واملعار�ض واال�ستمتاع ب�أوقات الفراغ‪.‬‬

‫‪Dubai - the exotic jewel of the United Arab Emirates. Bordered‬‬ ‫‪by deserts and beaches, Dubai provides stark contrasts, from‬‬ ‫‪intriguing Islamic culture to the ultra-modern, high-tech metropolis‬‬ ‫‪of the 21st century. The city is a magnificent expression of an‬‬ ‫‪incredible vision and an uncompromising statement of success‬‬ ‫‪and opportunity.‬‬ ‫‪Dubai has something for everyone, from vacationers seeking‬‬ ‫‪a relaxing break away from the pressures of work, to business‬‬ ‫‪travelers looking for a new exciting experience. The emirate is an‬‬ ‫‪international conference, exhibition and leisure destination..‬‬

‫الـ ـ ـ ــمنـ ـ ـ ـ ــاخ‬

‫‪ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om‬‬

‫تتنا�سب مالب�س ال�صيف اخلفيفة مع معظم �أوقات العام‪� ،‬إال �أنه قد تكون هناك‬ ‫حاجة �إىل ال�سرتات والقم�صان ال�شتوية الثقيلة خالل �أ�شهر ال�شتاء‪ ،‬وخا�صة يف‬ ‫الأوقات امل�سائية‪ .‬ومقارنة ببع�ض الأجزاء املعينة يف منطقة ال�شرق الأو�سط‪،‬‬ ‫تتميز دبي بنمط زي �شديد الراحة وباعث على اال�سرتخاء‪ .‬ومع ذلك يجب‬ ‫توخي احلذر بعدم الظهور مبظهر غري الئق يف الأماكن العامة من خالل ارتداء‬ ‫املالب�س املك�شوفة‪ ،‬على �سبيل املثال‪ ،‬الف�ساتني الق�صرية �أو التنانري ال�شديدة‬ ‫ال ِق َ�صر �أو القم�صان والقطع العلوية ال�ضيقة‪.‬‬ ‫ومن املقبول ارتداء ال�سراويل الق�صرية ومالب�س ال�سباحة والبيكيني على‬ ‫�أحوا�ض ال�سباحة وال�شواطئ‪ .‬و ُين�صح بارتداء نظارات �شم�سية عالية اجلودة‬ ‫و�صى‬ ‫وعد�سات ذات درجة لون متقلبة له�ؤالء ممن يرتدون نظارات طبية‪ .‬كما ُي َ‬ ‫بو�ضع قبعات �أو و�سيلة حماية فوق الر�أ�س عند التعر�ض لأ�شعة ال�شم�س املبا�شرة‪.‬‬

‫‪Dubai has a sub-tropical, arid climate. Sunny, blue skies can be‬‬ ‫‪expected most of the year. Rainfall is infrequent and‬‬ ‫‪irregular, falling mainly in winter. Temperatures range from a low‬‬ ‫‪of about 10.5°C /50 °F to a high of 48°C/118.4°F. The mean daily‬‬ ‫‪maximum is 24 °C/75.2 °F in January rising to 41°C/105.8‬‬ ‫‪°F in July.‬‬

‫‪Clothing‬‬

‫‪Lightweight summer clothing is suitable for most of the year,‬‬ ‫‪but sweaters or jackets may be needed for the winter months,‬‬ ‫‪especially in the evenings. Compared with certain parts of the‬‬ ‫‪Middle East, Dubai has a very relaxed dress code. However, care‬‬ ‫‪should be taken not to give offence by wearing clothing which‬‬ ‫‪may be considered revealing, for example low-cut dresses, very‬‬ ‫‪short skirts, or tight shirt or top in public.‬‬ ‫‪At the pool or on the beaches, trunks, swimsuits and bikinis are‬‬ ‫‪quite acceptable. Good quality sunglasses are advised, and photo‬‬ ‫‪chromatic lenses for those who wear spectacles. Hats, or some‬‬ ‫‪protection for the head, are advisable when in direct sunlight.‬‬

‫‪ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om‬‬

‫‪59‬‬

‫ال ـ ـ ـمـ ــالب�س‬

‫تتمتع دبي مبناخ جاف �شبه ا�ستوائي‪ ،‬حيث ال�سماء الزرقاء وال�شم�س‬ ‫ال�ساطعة معظم �أيام العام‪ .‬وقليلاً ما تهطل الأمطار وعلى نحو غري‬ ‫منتظم‪ ،‬وبخا�صة يف ف�صل ال�شتاء‪ .‬وترتاوح درجات احلرارة ال�صغرى‬ ‫ما بني ‪ 10.5‬درجة مئوية‪ 50/‬درجة فهرنهايت والكربى ما بني ‪ 48‬درجة‬ ‫مئوية‪ 118.4/‬درجة فهرنهايت‪ ،‬لت�صل �أق�صى معدالتها �أثناء النهار عند‬ ‫‪ 24‬درجة مئوية‪ 75/‬درجة فهرنهايت يف �شهر يناير وترتفع ُم�سجلة ‪41‬‬ ‫درجة مئوية‪ 105.8/‬فهرنهايت يف �شهر يوليو‪.‬‬

‫‪Climate‬‬

‫‪58‬‬

‫اخــتبـروا دبي‬

‫‪Experience Dubai‬‬

‫الثقافة ومنط احلياة‬

‫‪Culture & Lifestyle‬‬

‫تت�أ�صل ثقافة دبي ومتتد جذورها يف التقاليد الإ�سالمية املهيمنة على �شبه اجلزيرة العربية‪ ،‬ولكون الكيا�سة وح�سن ال�ضيافة‬ ‫من بني �أميز الف�ضائل التي حتظى بالتقدير يف العامل العربي‪ ،‬ف�إن �أكرث ما يفنت الزوار الدفء والود اللذان ُيعرف بهما‬ ‫�سكان الإمارة‪.‬‬ ‫ويتميز جمتمع دبي بقدر كبري من ال�سماحة التي تغطي �أمناط احلياة املختلفة‪ ،‬حيث يتمتع الأجانب باحلرية الكاملة يف‬ ‫ممار�سة �شعائرهم الدينية‪ ،‬كما ُتقدم امل�شروبات الكحولية يف الفنادق‪ ،‬ب�شرط �إظهار ال�سلوك الالئق‪� ،‬إ�ضافة �إىل حرية‬ ‫ارتداء �أمناط الزي املختلفة‪ .‬وال تواجه الن�ساء �أي نوع من �أنواع التفرقة فيحق لهن قيادة ال�سيارات والتجول دون حرا�سة‪.‬‬ ‫وبالرغم من التطور االقت�صادي ال�سريع الذي �شهدته الإمارة يف ال�سنوات الأخرية‪ ،‬ف�إن دبي تظل متم�سكة برتاثها‪ ،‬حيث‬ ‫متنف�سا كب ًريا يف‬ ‫يرتدي املواطنون املحليون الزي الوطني التقليدي وغطاء الر�أ�س‪ .‬وجتد الثقافة العربية والفنون ال�شعبية‬ ‫ً‬ ‫ال�شعر والرق�ص والأغاين والفن التقليدي‪ .‬كما ُتعد الأعرا�س واالحتفاالت الأخرى منا�سبات ناب�ضة باحلياة زاخرة بالأجواء‬ ‫االحتفالية واملو�سيقى ال�صاخبة‪ .‬ويتوا�صل ال�شغف مبمار�سة الريا�ضات التقليدية مثل ريا�ضة ال�صيد بال�صقور و�سباق الإبل‬ ‫و�سباق املراكب ال�شراعية يف البحر‪.‬‬

‫اللغ ـ ــة والدين‬

‫‪among the most highly prized of virtues, and the visitor is sure to be charmed by the genuine‬‬ ‫‪warmth and friendliness of the people.‬‬ ‫‪Dubai society is marked by a high degree of tolerance for different lifestyles. Foreigners are free to‬‬ ‫‪practice their own religion, alcohol is served in hotels and, provided reasonable discretion is shown,‬‬ ‫‪the dress code is liberal. Women face no discrimination and may drive and walk around unescorted.‬‬ ‫‪Despite rapid economic development in recent years, Dubai remains close to its heritage. Local citi‬‬ ‫‪zens dress in traditional robes and headdress. Arab culture and folklore find expression in poetry,‬‬ ‫‪dancing, songs and traditional art. Weddings and other celebrations are colorful occasions of feast‬‬‫‪ing and music. Traditional sports such as falconry, camel racing and dhow racing at sea continue‬‬ ‫‪to thrive.‬‬

‫‪Language & Religion‬‬

‫‪ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om‬‬

‫ُتعد اللغة العربية اللغة الر�سمية لهذه الإمارة �إال �أن اللغة الإجنليزية ُت�ستخدم‬ ‫و ُتفهم على نطاق وا�سع‪ ،‬وي�شيع ا�ستخدام اللغتني يف جمال الأعمال والتجارة‪.‬‬ ‫والإ�سالم هو الديانة الر�سمية حيث ينت�شر عدد كبري من امل�ساجد يف جميع �أنحاء‬ ‫املدينة‪ .‬وتلقى الديانات الأخرى قد ًرا كب ًريا من االحرتام والتبجيل حيث يوجد‬ ‫يف دبي كني�ستان م�سيحيتان هما‪� :‬سانت ماري (الكني�سة الرومانية الكاثوليكية)‬ ‫وكني�سة هويل ترينيتي (املتعددة الطوائف)‪.‬‬

‫الت�صوير الفوتوغرايف‬ ‫ُي�سمح لل�سياح بالتقاط ال�صور الفوتوغرافية العادية‪� ،‬إال �أن ت�صوير الن�ساء‬ ‫وجارحا للكرامة‪ .‬ومن الالئق � ً‬ ‫أي�ضا طلب الإذن‬ ‫امل�سلمات يعد �أم ًرا مهي ًنا‬ ‫ً‬ ‫قبل التقاط �صور فوتوغرافية للرجال‪.‬‬

‫الـ ـ ـ ـع ـ ـمـ ـ ـلـ ــة‬ ‫ُيعد الدرهم وحدة العملة الإماراتية وهو ي�ساوي ‪ 100‬فل�س‪ ،‬ويحظى الدرهم‬ ‫بحق ال�سحب اخلا�ص ب�صندوق النقد الدويل‪ .‬ولقد حقق ثبا ًتا كب ًريا يف‬ ‫مواجهة الدوالر الأمريكي منذ نهاية عام ‪ 1980‬مبتو�سط �سعر يقرتب من‬ ‫دوالر �أمريكي واحد لكل ‪ 3.67‬دراهم �إماراتية‪.‬‬

‫‪The official language is Arabic but English is widely spoken and‬‬ ‫‪understood. Both languages are commonly used in business and‬‬ ‫‪commerce. Islam is the official religion of the UAE and there are‬‬ ‫‪a large number of mosques throughout the city. Other religions‬‬ ‫‪are respected and Dubai has two Christian churches, St Mary’s‬‬ ‫‪(Roman Catholic) and Holy Trinity (inter-denominational).‬‬

‫‪Photography‬‬ ‫‪Normal tourist photography is allowed, however it is considered‬‬ ‫‪offensive to photograph Muslim women. It is also courteous to‬‬ ‫‪request permission before photographing men.‬‬

‫‪Currency‬‬ ‫‪The monetary unit is the dirham which is divided into 100‬‬ ‫‪fills. The dirham is linked to the Special Drawing Right of the‬‬ ‫‪International Monetary Fund. It has been held constant against‬‬ ‫‪the US dollar since the end of 1980 at a mid-rate of approxi‬‬‫‪mately US$1= Dh3.67‬‬

‫‪ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om‬‬

‫‪61‬‬

‫‪Dubai’s culture is firmly rooted in the Islamic traditions of Arabia. Courtesy and hospitality are‬‬

‫‪60‬‬

On Thursday, 16th January 2014 | 20:00 hrs Al Badia Golf Club, InterContinental Dubai Festival City Dubai - United Arab Emirates Shuttle buses will leave at 1915 hrs from Grand Hyatt Dubai Movenpick Crowne Plaza Deira Raffles Dubai

‫ﺣﻔﻞ ﺍﻟﻌﺸﺎﺀ‬

20:00 ‫ | ﻓﻲ ﲤﺎﻡ ﺍﻟﺴﺎﻋﺔ‬2014 ‫ ﻳﻨﺎﻳﺮ‬16 ‫ﻳﻮﻡ ﺍﳋﻤﻴﺲ ﺍﳌﻮﺍﻓﻖ‬ ،‫ﻧﺎﺩﻱ ﺍﻟﺒﺎﺩﻳﺔ ﻟﻠﺠﻮﻟﻒ‬ ‫ﻓﻨﺪﻕ ﺇﻧﺘﺮﻛﻮﻧﺘﻴﻨﻨﺘﺎﻝ ﺩﺑﻲ ﻓﺴﺘﻴﻔﺎﻝ ﺳﻴﺘﻲ‬ ‫ﺩﺑﻲ – ﺍﻹﻣﺎﺭﺍﺕ ﺍﻟﻌﺮﺑﻴﺔ ﺍﳌﺘﺤﺪﺓ‬ ‫ ﻣﻦ‬19:15 ‫ﺗﻨﻄﻠﻖ ﺣﺎﻓﻼﺕ ﺍﻟﻨﻘﻞ )ﺫﻫﺎﺑﹰﺎ ﻭ ﺇﻳﺎﺑﹰﺎ( ﻓﻲ ﲤﺎﻡ ﺍﻟﺴﺎﻋﺔ‬ ‫ﻓﻨﺪﻕ ﺟﺮﺍﻧﺪ ﺣﻴﺎﺓ ﺩﺑﻲ‬ ‫ﻓﻨﺪﻕ ﻣﻮﻓﻨﺒﻴﻚ‬ ‫ﻓﻨﺪﻕ ﻛﺮﺍﻭﻥ ﺑﻼﺯﺍ ﺩﻳﺮﺓ‬ ‫ﻓﻨﺪﻕ ﺭﺍﻓﻠﺰ ﺩﺑﻲ‬

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Gala Dinner

Thanks to All Our Sponsors & Exhibitors for Their Support

CIMZIA® is the only PEGylated anti-TNF.

Main Sponsor

Helps RA patients move forward fast

Platinum Sponsors

Cimzia® Abbreviated Product Information

Silver Sponsors

Bronze Sponsors

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

CIMZIA®—the clinical profile that helps you predict if your patients are on their way to improved long-term outcomes or if a change in treatment is required1,2

CIM-NBP-202-August-2013

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Gold Sponsors

66 ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

Notes Notes

68 69

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om

WGFXEL7013030

ww w.P anA r abR h eum at o log y 201 4 Dub a i.c om